1
|
Nagato T, Komatsuda H, Hayashi R, Takahara M, Ujiie N, Kosaka A, Ohkuri T, Oikawa K, Sato R, Wakisaka R, Kono M, Yamaki H, Ohara K, Kumai T, Kishibe K, Katada A, Hayashi T, Kobayashi H. Soluble CD27 as a predictive biomarker for intra-tumoral CD70/CD27 interaction in nasopharyngeal carcinoma. Cancer Sci 2024; 115:1073-1084. [PMID: 38279834 PMCID: PMC11007004 DOI: 10.1111/cas.16079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Revised: 12/26/2023] [Accepted: 01/04/2024] [Indexed: 01/29/2024] Open
Abstract
In CD70-expressing tumors, the interaction of CD70 on tumor cells with its lymphocyte receptor, CD27, is thought to play a role in immunosuppression in the tumor microenvironment and elevated serum levels of soluble CD27 (sCD27). Previous studies showed that CD70 is expressed in nasopharyngeal carcinoma (NPC), an Epstein-Barr virus (EBV)-related malignancy. However, the association between intratumoral CD70/CD27 expression and serum levels of sCD27 in NPC remains unclear. In the present study, we show that CD70 is primarily expressed by tumor cells in NPC and that CD27-positive lymphocytes infiltrate around tumor cells. NPC patients with CD27-positive lymphocytes had significantly better prognosis than patients lacking these cells. In addition, high CD70 expression by tumor cells tended to be correlated with shorter survival in NPC patients with CD27-positive lymphocytes. Serum sCD27 levels were significantly increased in patients with NPC and provided good diagnostic accuracy for discriminating patients from healthy individuals. The concentration of serum sCD27 in patients with CD70-positive NPC with CD27-positive lymphocytes was significantly higher than in patients with tumors negative for CD70 and/or CD27, indicating that the intratumoral CD70/CD27 interaction boosts the release of sCD27. Furthermore, positive expression of CD70 by NPC cells was significantly correlated with EBV infection. Our results suggest that CD70/CD27-targeted immunotherapies may be promising treatment options and that sCD27 may become an essential tool for evaluating the applicability of these therapies by predicting the intratumoral CD70/CD27 interaction in NPC.
Collapse
Affiliation(s)
- Toshihiro Nagato
- Department of PathologyAsahikawa Medical UniversityAsahikawaJapan
| | - Hiroki Komatsuda
- Department of PathologyAsahikawa Medical UniversityAsahikawaJapan
- Department of Otolaryngology‐Head and Neck SurgeryAsahikawa Medical UniversityAsahikawaJapan
| | - Ryusuke Hayashi
- Department of Otolaryngology‐Head and Neck SurgeryAsahikawa Medical UniversityAsahikawaJapan
| | - Miki Takahara
- Department of Otolaryngology‐Head and Neck SurgeryAsahikawa Medical UniversityAsahikawaJapan
- Department of Innovative Head and Neck Cancer Research and TreatmentAsahikawa Medical UniversityAsahikawaJapan
| | - Nanami Ujiie
- Department of PathologyAsahikawa Medical UniversityAsahikawaJapan
- Department of Thoracic Surgery and Breast SurgeryAsahikawa Medical University HospitalAsahikawaJapan
| | - Akemi Kosaka
- Department of PathologyAsahikawa Medical UniversityAsahikawaJapan
| | - Takayuki Ohkuri
- Department of PathologyAsahikawa Medical UniversityAsahikawaJapan
| | - Kensuke Oikawa
- Department of PathologyAsahikawa Medical UniversityAsahikawaJapan
| | - Ryosuke Sato
- Department of Otolaryngology‐Head and Neck SurgeryAsahikawa Medical UniversityAsahikawaJapan
| | - Risa Wakisaka
- Department of Otolaryngology‐Head and Neck SurgeryAsahikawa Medical UniversityAsahikawaJapan
| | - Michihisa Kono
- Department of Otolaryngology‐Head and Neck SurgeryAsahikawa Medical UniversityAsahikawaJapan
| | - Hidekiyo Yamaki
- Department of Otolaryngology‐Head and Neck SurgeryAsahikawa Medical UniversityAsahikawaJapan
| | - Kenzo Ohara
- Department of Otolaryngology‐Head and Neck SurgeryAsahikawa Medical UniversityAsahikawaJapan
| | - Takumi Kumai
- Department of Otolaryngology‐Head and Neck SurgeryAsahikawa Medical UniversityAsahikawaJapan
- Department of Innovative Head and Neck Cancer Research and TreatmentAsahikawa Medical UniversityAsahikawaJapan
| | - Kan Kishibe
- Department of Otolaryngology‐Head and Neck SurgeryAsahikawa Medical UniversityAsahikawaJapan
| | - Akihiro Katada
- Department of Otolaryngology‐Head and Neck SurgeryAsahikawa Medical UniversityAsahikawaJapan
| | - Tatsuya Hayashi
- Department of Otolaryngology‐Head and Neck SurgeryAsahikawa Medical UniversityAsahikawaJapan
| | - Hiroya Kobayashi
- Department of PathologyAsahikawa Medical UniversityAsahikawaJapan
| |
Collapse
|
2
|
Seesan T, Abd El-Sadek I, Mukherjee P, Zhu L, Oikawa K, Miyazawa A, Shen LTW, Matsusaka S, Buranasiri P, Makita S, Yasuno Y. Erratum: Deep convolutional neural networks-based scatterer density and resolution estimators in optical coherence tomography: erratum. Biomed Opt Express 2024; 15:1694-1696. [PMID: 38495720 PMCID: PMC10942684 DOI: 10.1364/boe.519744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/25/2024] [Indexed: 03/19/2024]
Abstract
[This corrects the article on p. 168 in vol. 13, PMID: 35154862.].
Collapse
Affiliation(s)
- Thitiya Seesan
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
- Department of Physics, School of Science, King Mongkut’s Institute of Technology Ladkrabang, Ladkrabang, Bangkok, Thailand
| | - Ibrahim Abd El-Sadek
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
- Department of Physics, Faculty of Science, Damietta University, New Damietta City, Damietta, Egypt
| | - Pradipta Mukherjee
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Lida Zhu
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Kensuke Oikawa
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Arata Miyazawa
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
- Sky technology Inc., Tsukuba, Ibaraki, Japan
| | - Larina Tzu-Wei Shen
- Clinical Research and Regional Innovation, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| | - Satoshi Matsusaka
- Clinical Research and Regional Innovation, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| | - Prathan Buranasiri
- Department of Physics, School of Science, King Mongkut’s Institute of Technology Ladkrabang, Ladkrabang, Bangkok, Thailand
| | - Shuichi Makita
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Yoshiaki Yasuno
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
| |
Collapse
|
3
|
Sakai Y, Oikawa K, Matsukawa M. Collision tumor of spindle cell lipoma arising from perirenal tissue and acquired cystic disease-associated renal cell carcinoma: A rare case report. IJU Case Rep 2023; 6:314-317. [PMID: 37667768 PMCID: PMC10475343 DOI: 10.1002/iju5.12617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2022] [Accepted: 07/13/2023] [Indexed: 09/06/2023] Open
Abstract
Introduction Collision tumors are a rare phenomenon defined as two or more histologically distinct tumors that are in contact with each other. Case presentation The patient was a man with a history of end-stage diabetic nephropathy under hemodialysis treatment for 15 years. A plain computed tomography scan showed a 4.3 cm mass with obscured margins in the right perirenal fat of the lower pole kidney. On T2-weighted magnetic resonance imaging, the lesion showed heterogeneous signal intensity with a partially cystic component. A radical nephrectomy was performed. Histopathological and immunohistochemical examination revealed collision tumors constituted of a spindle cell lipoma covering the kidney surface underneath the perirenal fat and diffusely distributed acquired cystic disease-associated renal cell carcinoma in the renal parenchyma. Conclusion We report the first case of collision tumors comprising spindle cell lipoma and acquired cystic disease-associated renal cell carcinoma.
Collapse
Affiliation(s)
- Yasuyuki Sakai
- Department of UrologyTakikawa Municipal HospitalTakikawaHokkaidoJapan
- Present address:
Department of UrologySapporo Medical University School of MedicineSapporoHokkaidoJapan
| | - Kensuke Oikawa
- Division of Pathology, Department of NursingAsahikawa Medical University HospitalAsahikawaHokkaidoJapan
| | | |
Collapse
|
4
|
Kosaka A, Yajima Y, Yasuda S, Komatsuda H, Nagato T, Oikawa K, Kobayashi H, Ohkuri T. Celecoxib promotes the efficacy of STING-targeted therapy by increasing antitumor CD8 + T-cell functions via modulating glucose metabolism of CD11b + Ly6G + cells. Int J Cancer 2023; 152:1685-1697. [PMID: 36495276 DOI: 10.1002/ijc.34394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Revised: 11/20/2022] [Accepted: 11/30/2022] [Indexed: 12/14/2022]
Abstract
Recent studies have shown that activation of the cGAS-STING pathway is a key process in antitumor immune responses and various kinds of STING agonists have been developed for cancer immunotherapy. Despite promising preclinical studies, preliminary clinical results have shown only a modest effect of STING agonists. There is therefore a need to develop more effective treatment strategies. Based on previous observations that COX-2 is frequently overexpressed not only in a variety of cancers but also in tumor myeloid cells and that it suppresses antitumor immunity and promotes tumor survival by producing PGE2, we investigated the antitumor effects of combination therapy with a STING agonist cGAMP and the selective COX-2 inhibitor celecoxib in mouse models. Combination treatment with cGAMP and celecoxib inhibited tumor growth compared with either monotherapy, and the combination therapy induced both local and systemic antitumor immunity. cGAMP treatment decreased PD-1 expression on tumor-infiltrating T-cells and enhanced T-cell activation in tumor-draining lymph nodes regardless of the presence of celecoxib. Meanwhile, although celecoxib treatment did not alter the frequency of CD4+ CD25+ Foxp3+ regulatory T-cells, it enhanced the expression of costimulatory molecules and glycolysis-associated genes in tumor-infiltrating CD11b+ Ly6G+ cells. Moreover, we also found that celecoxib decreased lactate efflux and increased the frequency of IFN-γ- and TNF-α-producing CD8+ T-cells in the tumor microenvironment. Taken together, our findings suggest that combined treatment with celecoxib may be an effective strategy to improve the antitumor efficacy of STING agonists.
Collapse
Affiliation(s)
- Akemi Kosaka
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Yuki Yajima
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.,Department of Oral and Maxillofacial Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Shunsuke Yasuda
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.,Respiratory and Breast Center, Asahikawa Medical University Hospital, Asahikawa, Japan
| | - Hiroki Komatsuda
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.,Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Toshihiro Nagato
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Kensuke Oikawa
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Hiroya Kobayashi
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Takayuki Ohkuri
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| |
Collapse
|
5
|
Nagato T, Komatsuda H, Hayashi R, Takahara M, Kishibe K, Yasuda S, Yajima Y, Kosaka A, Ohkuri T, Oikawa K, Harabuchi S, Kono M, Yamaki H, Wakisaka R, Hirata-Nozaki Y, Ohara K, Kumai T, Katada A, Hayashi T, Harabuchi Y, Kobayashi H. Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy. Cancer Immunol Immunother 2023:10.1007/s00262-023-03394-7. [PMID: 36811663 DOI: 10.1007/s00262-023-03394-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Accepted: 01/31/2023] [Indexed: 02/24/2023]
Abstract
The engagement of CD27 on lymphocytes with its ligand, CD70, on tumors is believed to mediate tumor immune evasion and the elevation of serum soluble CD27 (sCD27) levels in patients with CD70-positive malignancies. We previously showed that CD70 is expressed in extranodal natural killer/T-cell lymphoma, nasal type (ENKL), an Epstein-Barr virus (EBV)-related malignancy. However, little is known about serum sCD27 expression and its association with the clinical characteristics of, and the CD27/CD70 interaction in, ENKL. In the present study, we show that serum sCD27 is significantly elevated in the sera of patients with ENKL. The levels of serum sCD27 provided excellent diagnostic accuracy for discriminating patients with ENKL from healthy subjects, correlated positively with the levels of other diagnostic markers (lactate dehydrogenase, soluble interleukin-2 receptor, and EBV-DNA), and decreased significantly following treatment. Elevated serum sCD27 levels also correlated significantly with advanced clinical stage and tended to correspond with shorter survival, in patients with ENKL. Immunohistochemistry indicated that CD27-positive tumor-infiltrating immune cells exist adjacent to CD70-positive lymphoma cells. In addition, serum sCD27 levels in patients with CD70-positive ENKL were significantly higher than those in patients with CD70-negative ENKL, suggesting that the intra-tumoral CD27/CD70 interaction boosts the release of sCD27 in serum. Furthermore, the EBV-encoded oncoprotein latent membrane protein 1 upregulated CD70 expression in ENKL cells. Our results suggest that sCD27 may serve as a novel diagnostic biomarker and also may serve as a tool for evaluating the applicability of CD27/CD70-targeted therapies by predicting intra-tumoral CD70 expression and CD27/CD70 interaction in ENKL.
Collapse
Affiliation(s)
- Toshihiro Nagato
- Department of Pathology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Japan.
| | - Hiroki Komatsuda
- Department of Pathology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Japan.,Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Ryusuke Hayashi
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Miki Takahara
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.,Department of Innovative Research for Diagnosis and Treatment of Head and Neck Cancer, Asahikawa Medical University, Asahikawa, Japan
| | - Kan Kishibe
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Shunsuke Yasuda
- Department of Pathology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Japan.,Respiratory and Breast Center, Asahikawa Medical University Hospital, Asahikawa, Japan
| | - Yuki Yajima
- Department of Pathology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Japan.,Department of Oral and Maxillofacial Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Akemi Kosaka
- Department of Pathology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Japan
| | - Takayuki Ohkuri
- Department of Pathology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Japan
| | - Kensuke Oikawa
- Department of Pathology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Japan
| | - Shohei Harabuchi
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Michihisa Kono
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Hidekiyo Yamaki
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Risa Wakisaka
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Yui Hirata-Nozaki
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Kenzo Ohara
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Takumi Kumai
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.,Department of Innovative Research for Diagnosis and Treatment of Head and Neck Cancer, Asahikawa Medical University, Asahikawa, Japan
| | - Akihiro Katada
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Tatsuya Hayashi
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Yasuaki Harabuchi
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.,Department of Otolaryngology-Head and Neck Surgery, Hokuto Hospital, Obihiro, Japan
| | - Hiroya Kobayashi
- Department of Pathology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Japan.
| |
Collapse
|
6
|
Zhu L, Makita S, Oida D, Miyazawa A, Oikawa K, Mukherjee P, Lichtenegger A, Distel M, Yasuno Y. Erratum: Computational refocusing of Jones matrix polarization-sensitive optical coherence tomography and investigation of defocus-induced polarization artifacts: publisher's note. Biomed Opt Express 2022; 13:3520. [PMID: 35781977 PMCID: PMC9208586 DOI: 10.1364/boe.464290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/16/2022] [Indexed: 06/15/2023]
Abstract
[This corrects the article on p. 2975 in vol. 13.].
Collapse
Affiliation(s)
- Lida Zhu
- Computational Optics Group,
University of Tsukuba, Tsukuba, Ibaraki,
Japan
| | - Shuichi Makita
- Computational Optics Group,
University of Tsukuba, Tsukuba, Ibaraki,
Japan
| | - Daisuke Oida
- Computational Optics Group,
University of Tsukuba, Tsukuba, Ibaraki,
Japan
| | - Arata Miyazawa
- Computational Optics Group,
University of Tsukuba, Tsukuba, Ibaraki,
Japan
| | - Kensuke Oikawa
- Computational Optics Group,
University of Tsukuba, Tsukuba, Ibaraki,
Japan
- Sky Technology
Inc., Tsukuba, Ibaraki, Japan
| | - Pradipta Mukherjee
- Computational Optics Group,
University of Tsukuba, Tsukuba, Ibaraki,
Japan
| | | | - Martin Distel
- Computational Optics Group,
University of Tsukuba, Tsukuba, Ibaraki,
Japan
- Center for Medical Physics and Biomedical
Engineering, Medical University of Vienna,
Vienna, Austria
| | - Yoshiaki Yasuno
- Innovative Cancer Models, St.
Anna Children’s Cancer Research Institute,
Vienna, Austria
| |
Collapse
|
7
|
Yajima Y, Kosaka A, Ishibashi K, Yasuda S, Komatsuda H, Nagato T, Oikawa K, Kitada M, Takekawa M, Kumai T, Ohara K, Ohkuri T, Kobayashi H. A tumor metastasis-associated molecule TWIST1 is a favorable target for cancer immunotherapy due to its immunogenicity. Cancer Sci 2022; 113:2526-2535. [PMID: 35579200 PMCID: PMC9357613 DOI: 10.1111/cas.15429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2022] [Revised: 05/09/2022] [Accepted: 05/11/2022] [Indexed: 11/30/2022] Open
Abstract
Although neoantigens are one of the most favorable targets in cancer immunotherapy, it is less versatile and costly to apply neoantigen-derived cancer vaccines to patients due to individual variation. It is, therefore, important to find highly immunogenic antigens among tumor-specific or associated antigens, which are shared among patients. Considering the cancer immunoediting theory, immunogenic tumor cells cannot survive in early phase of tumor progression including two processes: elimination and equilibrium. We hypothesized that highly immunogenic molecules are allowed to be expressed in tumor cells after immune suppressive tumor microenvironment was established, if these molecules contribute to tumor survival. In the current study, we focused on TWIST1 as a candidate of highly immunogenic antigens because it is upregulated in tumor cells under hypoxia and promotes tumor metastasis, which are observed in late phase of tumor progression. We demonstrated that TWIST1 had an immunogenic peptide sequence TWIST1140-162 , which effectively activated TWIST1-specific CD4+ T-cells. In a short-term culture system, we detected more TWIST1-specific responses in breast cancer patients than in healthy donors. Vaccination with the TWIST1 peptide also showed efficient expansion of TWIST1-reactive HTLs in humanized mice. These findings indicate that TWIST1 is a highly immunogenic shared antigen and a favorable target for cancer immunotherapy.
Collapse
Affiliation(s)
- Yuki Yajima
- Department of Oral and Maxillofacial Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan
| | - Akemi Kosaka
- Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan
| | - Kei Ishibashi
- Breast Center, Asahikawa Medical University, Asahikawa, Hokkaido, Japan
| | - Shunsuke Yasuda
- Breast Center, Asahikawa Medical University, Asahikawa, Hokkaido, Japan
| | - Hiroki Komatsuda
- Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan
| | - Toshihiro Nagato
- Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan
| | - Kensuke Oikawa
- Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan
| | - Masahiro Kitada
- Breast Center, Asahikawa Medical University, Asahikawa, Hokkaido, Japan
| | - Masanori Takekawa
- Department of Oral and Maxillofacial Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan
| | - Takumi Kumai
- Otolaryngology-Head & Neck Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan
| | - Kenzo Ohara
- Otolaryngology-Head & Neck Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan
| | - Takayuki Ohkuri
- Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan
| | - Hiroya Kobayashi
- Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan
| |
Collapse
|
8
|
Zhu L, Makita S, Oida D, Miyazawa A, Oikawa K, Mukherjee P, Lichtenegger A, Distel M, Yasuno Y. Computational refocusing of Jones matrix polarization-sensitive optical coherence tomography and investigation of defocus-induced polarization artifacts. Biomed Opt Express 2022; 13:2975-2994. [PMID: 35774308 PMCID: PMC9203103 DOI: 10.1364/boe.454975] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Revised: 04/13/2022] [Accepted: 04/13/2022] [Indexed: 06/15/2023]
Abstract
Here we demonstrate a long-depth-of-focus imaging method using polarization sensitive optical coherence tomography (PS-OCT). This method involves a combination of Fresnel-diffraction-model-based phase sensitive computational refocusing and Jones-matrix based PS-OCT (JM-OCT). JM-OCT measures four complex OCT images corresponding to four polarization channels. These OCT images are computationally refocused as preserving the mutual phase consistency. This method is validated using a static phantom, postmortem zebrafish, and ex vivo porcine muscle samples. All the samples demonstrated successful computationally-refocused birefringence and degree-of-polarization-uniformity (DOPU) images. We found that defocusing induces polarization artifacts, i.e., incorrectly high birefringence values and low DOPU values, which are substantially mitigated by computational refocusing.
Collapse
Affiliation(s)
- Lida Zhu
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Shuichi Makita
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Daisuke Oida
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Arata Miyazawa
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
- Sky technology Inc., Tsukuba, Ibaraki, Japan
| | - Kensuke Oikawa
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Pradipta Mukherjee
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Antonia Lichtenegger
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
- Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria
| | - Martin Distel
- Innovative Cancer Models, St. Anna Children’s Cancer Research Institute, Vienna, Austria
| | - Yoshiaki Yasuno
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
| |
Collapse
|
9
|
Seesan T, Abd El-Sadek I, Mukherjee P, Zhu L, Oikawa K, Miyazawa A, Shen LTW, Matsusaka S, Buranasiri P, Makita S, Yasuno Y. Deep convolutional neural network-based scatterer density and resolution estimators in optical coherence tomography. Biomed Opt Express 2022; 13:168-183. [PMID: 35154862 PMCID: PMC8803045 DOI: 10.1364/boe.443343] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Revised: 11/03/2021] [Accepted: 11/25/2021] [Indexed: 05/02/2023]
Abstract
We present deep convolutional neural network (DCNN)-based estimators of the tissue scatterer density (SD), lateral and axial resolutions, signal-to-noise ratio (SNR), and effective number of scatterers (ENS, the number of scatterers within a resolution volume). The estimators analyze the speckle pattern of an optical coherence tomography (OCT) image in estimating these parameters. The DCNN is trained by a large number (1,280,000) of image patches that are fully numerically generated in OCT imaging simulation. Numerical and experimental validations were performed. The numerical validation shows good estimation accuracy as the root mean square errors were 0.23%, 3.65%, 3.58%, 3.79%, and 6.15% for SD, lateral and axial resolutions, SNR, and ENS, respectively. The experimental validation using scattering phantoms (Intralipid emulsion) shows reasonable estimations. Namely, the estimated SDs were proportional to the Intralipid concentrations, and the average estimation errors of lateral and axial resolutions were 1.36% and 0.68%, respectively. The scatterer density estimator was also applied to an in vitro tumor cell spheroid, and a reduction in the scatterer density during cell necrosis was found.
Collapse
Affiliation(s)
- Thitiya Seesan
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
- Department of Physics, School of Science, King Mongkut’s Institute of Technology Ladkrabang, Ladkrabang, Bangkok, Thailand
| | - Ibrahim Abd El-Sadek
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
- Department of Physics, Faculty of Science, Damietta University, New Damietta City, Damietta, Egypt
| | - Pradipta Mukherjee
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Lida Zhu
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Kensuke Oikawa
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Arata Miyazawa
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
- Sky Technology Inc., Tsukuba, Ibaraki, Japan
| | - Larina Tzu-Wei Shen
- Clinical Research and Regional Innovation, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| | - Satoshi Matsusaka
- Clinical Research and Regional Innovation, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| | - Prathan Buranasiri
- Department of Physics, School of Science, King Mongkut’s Institute of Technology Ladkrabang, Ladkrabang, Bangkok, Thailand
| | - Shuichi Makita
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Yoshiaki Yasuno
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, Japan
| |
Collapse
|
10
|
Kosaka A, Ishibashi K, Nagato T, Kitamura H, Fujiwara Y, Yasuda S, Nagata M, Harabuchi S, Hayashi R, Yajima Y, Ohara K, Kumai T, Aoki N, Komohara Y, Oikawa K, Harabuchi Y, Kitada M, Kobayashi H, Ohkuri T. CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes. J Exp Med 2021; 218:212661. [PMID: 34559187 PMCID: PMC8480673 DOI: 10.1084/jem.20200792] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Revised: 07/13/2021] [Accepted: 09/03/2021] [Indexed: 01/18/2023] Open
Abstract
Activation of STING signaling plays an important role in anti-tumor immunity, and we previously reported the anti-tumor effects of STING through accumulation of M1-like macrophages in tumor tissue treated with a STING agonist. However, myeloid cells express SIRPα, an inhibitory receptor for phagocytosis, and its receptor, CD47, is overexpressed in various cancer types. Based on our findings that breast cancer patients with highly expressed CD47 have poor survival, we evaluated the therapeutic efficacy and underlying mechanisms of combination therapy with the STING ligand cGAMP and an antagonistic anti-CD47 mAb using E0771 mouse breast cancer cells. Anti-CD47 mAb monotherapy did not suppress tumor growth in our setting, whereas cGAMP and anti-CD47 mAb combination therapy inhibited tumor growth. The combination therapy enhanced phagocytosis of tumor cells and induced systemic anti-tumor immune responses, which rely on STING and type I IFN signaling. Taken together, our findings indicate that coadministration of cGAMP and an antagonistic anti-CD47 mAb may be promising for effective cancer immunotherapy.
Collapse
Affiliation(s)
- Akemi Kosaka
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Kei Ishibashi
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.,Respiratory and Breast Center, Asahikawa Medical University Hospital, Asahikawa, Japan
| | - Toshihiro Nagato
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Hidemitsu Kitamura
- Division of Functional Immunology, Section of Disease Control, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
| | - Yukio Fujiwara
- Department of Cell Pathology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
| | - Syunsuke Yasuda
- Respiratory and Breast Center, Asahikawa Medical University Hospital, Asahikawa, Japan
| | - Marino Nagata
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Shohei Harabuchi
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.,Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Ryusuke Hayashi
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.,Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Yuki Yajima
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Kenzo Ohara
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Takumi Kumai
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Naoko Aoki
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Yoshihiro Komohara
- Department of Cell Pathology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
| | - Kensuke Oikawa
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Yasuaki Harabuchi
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Masahiro Kitada
- Respiratory and Breast Center, Asahikawa Medical University Hospital, Asahikawa, Japan
| | - Hiroya Kobayashi
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Takayuki Ohkuri
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| |
Collapse
|
11
|
Mitsui N, Oikawa K, Tanino M, Kinoshita M. SMARCB1 (INI1) retained but SMARCA4 (BRG1) negative atypical teratoid/rhabdoid tumor arising at the bilateral cerebellopontine angles: a case report. J Surg Case Rep 2021; 2021:rjab400. [PMID: 34611487 PMCID: PMC8485679 DOI: 10.1093/jscr/rjab400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2021] [Accepted: 08/20/2021] [Indexed: 11/17/2022] Open
Abstract
Most atypical teratoid/rhabdoid tumor (AT/RT) of the central nervous system shows an inactivation of SMARCB1 (INI1) and is considered as the hallmark of this neoplasm. However, AT/RT could exceptionally rarely present retained SMARCB1 (INI1) but inactivated SMARCA4 (BRG1). Here, the authors report a rare case of a 2-year-old boy with a SMARCB1 (INI1) retained but SMARCA4 (BRG1) negative AT/RT arising at the bilateral cerebellopontine angles mimicking neurofibromatosis type 2. The tumor was highly aggressive and was refractory to all treatment modalities. This case highlights the challenges during differential diagnosis of atypical cerebellopontine angle tumors of childhood and the importance of thoroughly investigating SMARCB1 (INI1) and SMARCA4 (BRG1) when AT/RT is suspected.
Collapse
Affiliation(s)
- Nobuyuki Mitsui
- Department of Neurosurgery, Asahikawa Medical University, Asahikawa, Japan
| | - Kensuke Oikawa
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Mishie Tanino
- Department of Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa, Japan
| | - Manabu Kinoshita
- Department of Neurosurgery, Asahikawa Medical University, Asahikawa, Japan
| |
Collapse
|
12
|
Oida D, Tomita K, Oikawa K, Wang TA, Makita S, Tsai MT, Yasuno Y. Computational multi-directional optical coherence tomography for visualizing the microstructural directionality of the tissue. Biomed Opt Express 2021; 12:3851-3864. [PMID: 34457384 PMCID: PMC8367225 DOI: 10.1364/boe.426125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Revised: 05/20/2021] [Accepted: 05/23/2021] [Indexed: 06/13/2023]
Abstract
We demonstrate computational multi-directional optical coherence tomography (OCT) to assess the directional property of tissue microstructure. This method is the combination of phase-sensitive volumetric OCT imaging and post-signal processing. The latter comprises of two steps. The first step is an intensity-directional analysis, which determines the dominant en face fiber orientations. The second step is the phase-directional imaging, which reveals the sub-resolution depth-orientation of the microstructure. The feasibility of the method was tested by assessing muscle and tendon samples. Stripe patterns with several sizes were visualized in the phase-directional images. In order to interpret these images, the muscle and tendon structures were numerically modeled, and the phase-directional images were generated from the numerical model. The similarity of the experimental and numerical results suggested that the stripe patterns correspond to the muscle fiber bundle and its crimping.
Collapse
Affiliation(s)
- Daisuke Oida
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki 305-8573, Japan
| | - Kiriko Tomita
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki 305-8573, Japan
| | - Kensuke Oikawa
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki 305-8573, Japan
| | - Tai-Ang Wang
- Institute of Photonic System, College of Photonics, National Chiao-Tung University, Tainan City 71150, Taiwan
| | - Shuichi Makita
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki 305-8573, Japan
| | - Meng-Tsan Tsai
- Department of Electrical Engineering, Chang Gung University, Taoyuan 33302, Taiwan
- Department of Neurosurgery, Chang Gung Memorial Hospital, Linkou, Taoyuan 33305, Taiwan
| | - Yoshiaki Yasuno
- Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki 305-8573, Japan
| |
Collapse
|
13
|
Kosaka A, Yajima Y, Hatayama M, Ikuta K, Sasaki T, Hirai N, Yasuda S, Nagata M, Hayashi R, Harabuchi S, Ohara K, Ohara M, Kumai T, Ishibashi K, Hirata-Nozaki Y, Nagato T, Oikawa K, Harabuchi Y, Celis E, Okumura T, Ohsaki Y, Kobayashi H, Ohkuri T. A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy. Cancer Sci 2021; 112:2705-2713. [PMID: 34009705 PMCID: PMC8253266 DOI: 10.1111/cas.14973] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Revised: 04/26/2021] [Accepted: 05/06/2021] [Indexed: 12/16/2022] Open
Abstract
Recent studies have revealed that tumor cells decrease their immunogenicity by epigenetically repressing the expression of highly immunogenic antigens to survive in immunocompetent hosts. We hypothesized that these epigenetically hidden “stealth” antigens should be favorable targets for cancer immunotherapy due to their high immunogenicity. To identify these stealth antigens, we treated human lung cell line A549 with DNA methyltransferase inhibitor 5‐aza‐2′‐deoxycytidine (5Aza) and its prodrug guadecitabine for 3 d in vitro and screened it using cDNA microarray analysis. We found that the gene encoding sperm equatorial segment protein 1 (SPESP1) was re‐expressed in cell lines including solid tumors and leukemias treated with 5Aza, although SPESP1 was not detected in untreated tumor cell lines. Using normal human tissue cDNA panels, we demonstrated that SPESP1 was not detected in normal human tissue except for testis and placenta. Moreover, we found using immunohistochemistry SPESP1 re‐expression in xenografts in BALB/c‐nu/nu mice that received 5Aza treatment. To assess the antigenicity of SPESP1, we stimulated human CD4+ T‐cells with a SPESP1‐derived peptide designed using a computer algorithm. After repetitive stimulation, SPESP1‐specific helper T‐cells were obtained; these cells produced interferon‐γ against HLA‐matched tumor cell lines treated with 5Aza. We also detected SPESP1 expression in freshly collected tumor cells derived from patients with acute myeloid leukemia or lung cancer. In conclusion, SPESP1 can be classified as a stealth antigen, a molecule encoded by a gene that is epigenetically silenced in tumor cells but serves as a highly immunogenic antigen suitable for cancer immunotherapy.
Collapse
Affiliation(s)
- Akemi Kosaka
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Yuki Yajima
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Mayumi Hatayama
- Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan
| | - Katsuya Ikuta
- Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan
| | - Takaaki Sasaki
- Respiratory Center, Asahikawa Medical University, Asahikawa, Japan
| | - Noriko Hirai
- Respiratory Center, Asahikawa Medical University, Asahikawa, Japan
| | - Syunsuke Yasuda
- Respiratory Center, Asahikawa Medical University, Asahikawa, Japan
| | - Marino Nagata
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Ryusuke Hayashi
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Shohei Harabuchi
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Kenzo Ohara
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Mizuho Ohara
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Takumi Kumai
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Kei Ishibashi
- Respiratory Center, Asahikawa Medical University, Asahikawa, Japan
| | - Yui Hirata-Nozaki
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Toshihiro Nagato
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Kensuke Oikawa
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Yasuaki Harabuchi
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Esteban Celis
- Georgia Cancer Center, Augusta University Medical College of Georgia, Augusta, GA, USA
| | - Toshikatsu Okumura
- Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan
| | - Yoshinobu Ohsaki
- Respiratory Center, Asahikawa Medical University, Asahikawa, Japan
| | - Hiroya Kobayashi
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Takayuki Ohkuri
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| |
Collapse
|
14
|
Nagata M, Kosaka A, Yajima Y, Yasuda S, Ohara M, Ohara K, Harabuchi S, Hayashi R, Funakoshi H, Ueda J, Kumai T, Nagato T, Oikawa K, Harabuchi Y, Esteban C, Ohkuri T, Kobayashi H. A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment. Cancer Immunol Immunother 2021; 70:2301-2312. [PMID: 33507344 DOI: 10.1007/s00262-021-02864-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Accepted: 01/15/2021] [Indexed: 01/22/2023]
Abstract
Stimulator of interferon genes (STING) contributes to anti-tumor immunity by activating antigen-presenting cells and inducing mobilization of tumor-specific T cells. A role for tumor-migrating neutrophils in the anti-tumor effect of STING-activating therapy has not been defined. We used mouse tumor transplantation models for assessing neutrophil migration into the tumor triggered by intratumoral treatment with STING agonist, 2'3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP). Intratumoral STING activation with cGAMP enhanced neutrophil migration into the tumor in an NF-κB/CXCL1/2-dependent manner. Blocking the neutrophil migration by anti-CXCR2 monoclonal antibody impaired T cell activation in tumor-draining lymph nodes (dLNs) and efficacy of intratumoral cGAMP treatment. Moreover, the intratumoral cGAMP treatment did not show any anti-tumor effect in type I interferon (IFN) signal-impaired mice in spite of enhanced neutrophil accumulation in the tumor. These results suggest that both neutrophil migration and type I interferon (IFN) induction by intratumoral cGAMP treatment were critical for T-cell activation of dLNs and the anti-tumor effect. In addition, we also performed in vitro analysis showing enhanced cytotoxicity of neutrophils by IFN-β1. Extrinsic STING activation triggers anti-tumor immune responses by recruiting and activating neutrophils in the tumor via two signaling pathways, CXCL1/2 and type I IFNs.
Collapse
Affiliation(s)
- Marino Nagata
- Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan
| | - Akemi Kosaka
- Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan
| | - Yuki Yajima
- Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan
| | - Syunsuke Yasuda
- Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan
| | - Mizuho Ohara
- Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan
| | - Kenzo Ohara
- Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan
| | - Shohei Harabuchi
- Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan
| | - Ryusuke Hayashi
- Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan
| | - Hiroshi Funakoshi
- Deprtment of Advanced Medical Science, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan
| | - Jun Ueda
- Deprtment of Advanced Medical Science, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan
| | - Takumi Kumai
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan
| | - Toshihiro Nagato
- Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan
| | - Kensuke Oikawa
- Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan
| | - Yasuaki Harabuchi
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan
| | - Celis Esteban
- Georgia Cancer Center, Augusta University Medical College of Georgia, Augusta, GA, USA
| | - Takayuki Ohkuri
- Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan.
| | - Hiroya Kobayashi
- Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan.
| |
Collapse
|
15
|
Hayashi R, Nagato T, Kumai T, Ohara K, Ohara M, Ohkuri T, Hirata-Nozaki Y, Harabuchi S, Kosaka A, Nagata M, Yajima Y, Yasuda S, Oikawa K, Kono M, Kishibe K, Takahara M, Katada A, Hayashi T, Celis E, Harabuchi Y, Kobayashi H. Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma. Oncoimmunology 2020; 10:1856545. [PMID: 33457076 PMCID: PMC7781841 DOI: 10.1080/2162402x.2020.1856545] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Placenta-specific 1 (PLAC1) is expressed primarily in placental trophoblasts but not in normal tissues and is a targetable candidate for cancer immunotherapy because it is a cancer testis antigen known to be up-regulated in various tumors. Although peptide epitopes capable of stimulating CD8 T cells have been previously described, there have been no reports of PLAC1 CD4 helper T lymphocyte (HTL) epitopes and the expression of this antigen in head and neck squamous cell carcinoma (HNSCC). Here, we show that PLAC1 is highly expressed in 74.5% of oropharyngeal and 51.9% of oral cavity tumors from HNSCC patients and in several HNSCC established cell lines. We also identified an HTL peptide epitope (PLAC131-50) capable of eliciting effective antigen-specific and tumor-reactive T cell responses. Notably, this peptide behaves as a promiscuous epitope capable of stimulating T cells in the context of more than one human leukocyte antigen (HLA)-DR allele and induces PLAC1-specific CD4 T cells that kill PLAC1-positive HNSCC cell lines in an HLA-DR-restricted manner. Furthermore, T-cells reactive to PLAC131-50 peptide were detected in the peripheral blood of HNSCC patients. These findings suggest that PLAC1 represents a potential target antigen for HTL based immunotherapy in HNSCC.
Collapse
Affiliation(s)
- Ryusuke Hayashi
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.,Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Toshihiro Nagato
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Takumi Kumai
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.,Department of Innovative Research for Diagnosis and Treatment of Head and Neck Cancer, Asahikawa Medical University, Asahikawa, Japan
| | - Kenzo Ohara
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Mizuho Ohara
- Department of Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Takayuki Ohkuri
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Yui Hirata-Nozaki
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Shohei Harabuchi
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Akemi Kosaka
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Marino Nagata
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Yuki Yajima
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.,Department of Oral and Maxillofacial Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Syunsuke Yasuda
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.,Respiratory and Breast Center, Asahikawa Medical University Hospital, Asahikawa, Japan
| | - Kensuke Oikawa
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Michihisa Kono
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Kan Kishibe
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Miki Takahara
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Akihiro Katada
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Tatsuya Hayashi
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.,Department of Innovative Research for Diagnosis and Treatment of Head and Neck Cancer, Asahikawa Medical University, Asahikawa, Japan
| | - Esteban Celis
- Cancer Immunology, Inflammation and Tolerance Program, Augusta University, Georgia Cancer Center, Augusta, GA, USA
| | - Yasuaki Harabuchi
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Hiroya Kobayashi
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| |
Collapse
|
16
|
Oikawa K, Oida D, Makita S, Yasuno Y. Bulk-phase-error correction for phase-sensitive signal processing of optical coherence tomography. Biomed Opt Express 2020; 11:5886-5902. [PMID: 33149994 PMCID: PMC7587287 DOI: 10.1364/boe.396666] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/11/2020] [Revised: 09/11/2020] [Accepted: 09/13/2020] [Indexed: 05/11/2023]
Abstract
We present a numerical phase stabilization method for phase-sensitive signal processing of optical coherence tomography (OCT). This method removes the bulk phase error caused by the axial bulk motion of the sample and the environmental perturbation during volumetric acquisition. In this method, the partial derivatives of the phase error are computed along both fast and slow scanning directions, so that the vectorial gradient field of the phase error is given. Then, the phase error is estimated from the vectorial gradient field by a newly developed line integration method; a smart integration path method. The performance of this method was evaluated by analyzing the spatial frequency spectra of en face OCT images, and it objectively shows the significant phase-error-correction ability of the method. The performance was also evaluated by observing computationally refocused en face images of ex vivo tissue samples, and it was found that the image quality was improved by the phase-error correction.
Collapse
|
17
|
Zhu L, Miyazawa A, Mukherjee P, Abd El-Sadek I, Oikawa K, Oida D, Yasuno Y. Numerical jitter estimation for swept source optical coherence tomography. Biomedical Imaging and Sensing Conference 2020 2020. [DOI: 10.1117/12.2573281] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/02/2023]
|
18
|
Ohara M, Ohara K, Kumai T, Ohkuri T, Nagato T, Hirata-Nozaki Y, Kosaka A, Nagata M, Hayashi R, Harabuchi S, Yajima Y, Oikawa K, Harabuchi Y, Sumi Y, Furukawa H, Kobayashi H. Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer. Cancer Immunol Immunother 2020; 69:989-999. [PMID: 32086539 DOI: 10.1007/s00262-020-02524-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2019] [Accepted: 02/16/2020] [Indexed: 12/31/2022]
Abstract
Colorectal cancer (CRC) patients with metastatic lesions have low 5-year survival rates. During metastasis, cancer cells often obtain unique characteristics such as epithelial-mesenchymal transition (EMT). Vimentin a biomarker contributes to EMT by changing cell shape and motility. Since abnormal phosphorylation is a hallmark of malignancy, targeting phosphorylated vimentin is a feasible approach for the treatment of metastatic tumors while sparing non-tumor cells. Recent evidence has revealed that both CD8 cytotoxic T lymphocytes (CTLs) and also CD4 helper T lymphocytes (HTLs) can distinguish post-translationally modified antigens from normal antigens. Here, we showed that the expression of phosphorylated vimentin was upregulated in metastatic sites of CRC. We also showed that a chemotherapeutic reagent augmented the expression of phosphorylated vimentin. The novel phosphorylated helper peptide epitopes from vimentin could elicit a sufficient T cell response. Notably, precursor lymphocytes that specifically reacted to these phosphorylated vimentin-derived peptides were detected in CRC patients. These results suggest that immunotherapy targeting phosphorylated vimentin could be promising for metastatic CRC patients.
Collapse
Affiliation(s)
- Mizuho Ohara
- Department of Pathology, Asahikawa Medical University, 2-1-1-1, Midorigaoka-Higashi, Asahikawa, 0788510, Japan.,Department of Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Kenzo Ohara
- Department of Pathology, Asahikawa Medical University, 2-1-1-1, Midorigaoka-Higashi, Asahikawa, 0788510, Japan.,Department of Otolaryngology-Head and Neck surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Takumi Kumai
- Department of Pathology, Asahikawa Medical University, 2-1-1-1, Midorigaoka-Higashi, Asahikawa, 0788510, Japan. .,Department of Otolaryngology-Head and Neck surgery, Asahikawa Medical University, Asahikawa, Japan. .,Department of Innovative Head and Neck Cancer Research and Treatment (IHNCRT), Asahikawa Medical University, 2-1-1-1, Midorigaoka-Higashi, Asahikawa, 0788510, Japan.
| | - Takayuki Ohkuri
- Department of Pathology, Asahikawa Medical University, 2-1-1-1, Midorigaoka-Higashi, Asahikawa, 0788510, Japan.
| | - Toshihiro Nagato
- Department of Pathology, Asahikawa Medical University, 2-1-1-1, Midorigaoka-Higashi, Asahikawa, 0788510, Japan
| | - Yui Hirata-Nozaki
- Department of Pathology, Asahikawa Medical University, 2-1-1-1, Midorigaoka-Higashi, Asahikawa, 0788510, Japan.,Department of Otolaryngology-Head and Neck surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Akemi Kosaka
- Department of Pathology, Asahikawa Medical University, 2-1-1-1, Midorigaoka-Higashi, Asahikawa, 0788510, Japan
| | - Marino Nagata
- Department of Pathology, Asahikawa Medical University, 2-1-1-1, Midorigaoka-Higashi, Asahikawa, 0788510, Japan
| | - Ryusuke Hayashi
- Department of Pathology, Asahikawa Medical University, 2-1-1-1, Midorigaoka-Higashi, Asahikawa, 0788510, Japan.,Department of Otolaryngology-Head and Neck surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Shohei Harabuchi
- Department of Pathology, Asahikawa Medical University, 2-1-1-1, Midorigaoka-Higashi, Asahikawa, 0788510, Japan.,Department of Otolaryngology-Head and Neck surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Yuki Yajima
- Department of Pathology, Asahikawa Medical University, 2-1-1-1, Midorigaoka-Higashi, Asahikawa, 0788510, Japan
| | - Kensuke Oikawa
- Department of Pathology, Asahikawa Medical University, 2-1-1-1, Midorigaoka-Higashi, Asahikawa, 0788510, Japan
| | - Yasuaki Harabuchi
- Department of Otolaryngology-Head and Neck surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Yasuo Sumi
- Department of Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Hiroyuki Furukawa
- Department of Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Hiroya Kobayashi
- Department of Pathology, Asahikawa Medical University, 2-1-1-1, Midorigaoka-Higashi, Asahikawa, 0788510, Japan
| |
Collapse
|
19
|
Harabuchi S, Kosaka A, Yajima Y, Nagata M, Hayashi R, Kumai T, Ohara K, Nagato T, Oikawa K, Ohara M, Harabuchi Y, Ohkuri T, Kobayashi H. Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma. Biochem Biophys Res Commun 2019; 522:408-414. [PMID: 31771883 DOI: 10.1016/j.bbrc.2019.11.107] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2019] [Accepted: 11/16/2019] [Indexed: 01/26/2023]
Abstract
Although cisplatin (CDDP) has been used as a major chemotherapeutic drug for head and neck squamous cell carcinoma (HNSCC), its impact on T-cell functions is controversial. Therefore, we investigated the immunologic effects of CDDP and antitumor effects by combination therapy of CDDP with a ligand for stimulator of interferon genes, cyclic guanosine monophosphate-adenosine monophosphate (cGAMP). Direct impacts of CDDP on T-cell functions were addressed by comparing T-cell functions between human subjects treated and untreated with CDDP. The immune responses and the efficacy of combination therapy using CDDP and cGAMP were assessed using BALB/c mice inoculated with mouse squamous cell carcinoma (SCC) cell lines. CDDP inhibited T-cell proliferation in a dose-dependent manner. T-cell functions of CDDP-treated HNSCC patients were comparable to those of healthy donors and CDDP-untreated HNSCC patients. In the mice bearing SCC cell lines, combination therapy using CDDP and cGAMP enhanced the gene expressions of CXCL9 and CXCL10 in the tumor tissues and inhibited tumor growth. The antitumor effect was cancelled by anti-CXCR3 monoclonal antibody. These findings suggest that the combination therapy using CDDP and an immunomodulating drug like cGAMP would be a rational cancer immunotherapy for patients with HNSCC.
Collapse
Affiliation(s)
- Shohei Harabuchi
- Department of Pathology, Head and Neck Surgery Asahikawa Medical University, Asahikawa Midorigaoka-Higashi 2-1-1, Asahikawa, Japan; Department of Otolaryngology, Head and Neck Surgery Asahikawa Medical University, Asahikawa Midorigaoka-Higashi 2-1-1, Asahikawa, Japan
| | - Akemi Kosaka
- Department of Pathology, Head and Neck Surgery Asahikawa Medical University, Asahikawa Midorigaoka-Higashi 2-1-1, Asahikawa, Japan
| | - Yuki Yajima
- Department of Pathology, Head and Neck Surgery Asahikawa Medical University, Asahikawa Midorigaoka-Higashi 2-1-1, Asahikawa, Japan
| | - Marino Nagata
- Department of Pathology, Head and Neck Surgery Asahikawa Medical University, Asahikawa Midorigaoka-Higashi 2-1-1, Asahikawa, Japan
| | - Ryusuke Hayashi
- Department of Pathology, Head and Neck Surgery Asahikawa Medical University, Asahikawa Midorigaoka-Higashi 2-1-1, Asahikawa, Japan; Department of Otolaryngology, Head and Neck Surgery Asahikawa Medical University, Asahikawa Midorigaoka-Higashi 2-1-1, Asahikawa, Japan
| | - Takumi Kumai
- Department of Otolaryngology, Head and Neck Surgery Asahikawa Medical University, Asahikawa Midorigaoka-Higashi 2-1-1, Asahikawa, Japan
| | - Kenzo Ohara
- Department of Pathology, Head and Neck Surgery Asahikawa Medical University, Asahikawa Midorigaoka-Higashi 2-1-1, Asahikawa, Japan; Department of Otolaryngology, Head and Neck Surgery Asahikawa Medical University, Asahikawa Midorigaoka-Higashi 2-1-1, Asahikawa, Japan
| | - Toshihiro Nagato
- Department of Pathology, Head and Neck Surgery Asahikawa Medical University, Asahikawa Midorigaoka-Higashi 2-1-1, Asahikawa, Japan
| | - Kensuke Oikawa
- Department of Pathology, Head and Neck Surgery Asahikawa Medical University, Asahikawa Midorigaoka-Higashi 2-1-1, Asahikawa, Japan
| | - Mizuho Ohara
- Department of Pathology, Head and Neck Surgery Asahikawa Medical University, Asahikawa Midorigaoka-Higashi 2-1-1, Asahikawa, Japan
| | - Yasuaki Harabuchi
- Department of Otolaryngology, Head and Neck Surgery Asahikawa Medical University, Asahikawa Midorigaoka-Higashi 2-1-1, Asahikawa, Japan
| | - Takayuki Ohkuri
- Department of Pathology, Head and Neck Surgery Asahikawa Medical University, Asahikawa Midorigaoka-Higashi 2-1-1, Asahikawa, Japan.
| | - Hiroya Kobayashi
- Department of Pathology, Head and Neck Surgery Asahikawa Medical University, Asahikawa Midorigaoka-Higashi 2-1-1, Asahikawa, Japan.
| |
Collapse
|
20
|
Hirata-Nozaki Y, Ohkuri T, Ohara K, Kumai T, Nagata M, Harabuchi S, Kosaka A, Nagato T, Ishibashi K, Oikawa K, Aoki N, Ohara M, Harabuchi Y, Uno Y, Takei H, Celis E, Kobayashi H. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. J Transl Med 2019; 17:207. [PMID: 31221178 PMCID: PMC6585001 DOI: 10.1186/s12967-019-1957-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Accepted: 06/13/2019] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND Head and neck squamous cell carcinoma (HNSCC) originates from squamous epithelium of the upper aerodigestive tract and is the most common malignancy in the head and neck region. Among HNSCCs, oropharynx squamous cell carcinoma (OSCC) has a unique profile and is associated with human papillomavirus infection. Recently, anti-programmed cell death-1 monoclonal antibody has yielded good clinical responses in recurrent and/or metastatic HNSCC patients. Therefore, programmed death-ligand 1 (PD-L1) may be a favorable target molecule for cancer immunotherapy. Although PD-L1-expressing malignant cells could be targeted by PD-L1-specific CD8+ cytotoxic T lymphocytes, it remains unclear whether CD4+ helper T lymphocytes (HTLs) recognize and kill tumor cells in a PD-L1-specific manner. METHODS The expression levels of PD-L1 and HLA-DR were evaluated using immunohistochemical analyses. MHC class II-binding peptides for PD-L1 were designed based on computer algorithm analyses and added into in vitro culture of HTLs with antigen-presenting cells to evaluate their stimulatory activity. RESULTS We found that seven of 24 cases of OSCC showed positive for both PD-L1 and HLA-DR and that PD-L1241-265 peptide efficiently activates HTLs, which showed not only cytokine production but also cytotoxicity against tumor cells in a PD-L1-dependent manner. Also, an adoptive transfer of the PD-L1-specific HTLs significantly inhibited growth of PD-L1-expressing human tumor cell lines in an immunodeficient mouse model. Importantly, T cell responses specific for the PD-L1241-265 peptide were detected in the HNSCC patients. CONCLUSIONS The cancer immunotherapy targeting PD-L1 as a helper T-cell antigen would be a rational strategy for HNSCC patients.
Collapse
Affiliation(s)
- Yui Hirata-Nozaki
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan.,Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
| | - Takayuki Ohkuri
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan.
| | - Kenzo Ohara
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan.,Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
| | - Takumi Kumai
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
| | - Marino Nagata
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
| | - Shohei Harabuchi
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan.,Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
| | - Akemi Kosaka
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
| | - Toshihiro Nagato
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan.,Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
| | - Kei Ishibashi
- Respiratory and Breast Center, Asahikawa Medical University Hospital, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
| | - Kensuke Oikawa
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
| | - Naoko Aoki
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
| | - Mizuho Ohara
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
| | - Yasuaki Harabuchi
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
| | - Yuji Uno
- Department of Pathology, Asahikawa Medical University Hospital, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
| | - Hidehiro Takei
- Department of Pathology, Asahikawa Medical University Hospital, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
| | - Esteban Celis
- Cancer Immunology, Inflammation and Tolerance Program, Augusta University Georgia Cancer Center, 1120 15th Street, Augusta, GA, 30912, USA
| | - Hiroya Kobayashi
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan.
| |
Collapse
|
21
|
Komiyama K, Nakamura M, Tanabe K, Niikura H, Fujimoto H, Oikawa K, Daida H, Yamamoto T, Nagao K, Takayama M. P6421Development of the clinical scoring system to predict in-hospital mortality in patients with acute myocardial infarction; comparison with the GRACE risk score. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- K Komiyama
- Tokyo CCU Network, Mitsui Memorial Hospital, Tokyo, Japan
| | | | - K Tanabe
- Mitsui Memorial Hospital, Tokyo, Japan
| | | | | | | | - H Daida
- Tokyo CCU Network, Tokyo, Japan
| | | | - K Nagao
- Tokyo CCU Network, Tokyo, Japan
| | | | | |
Collapse
|
22
|
Ohara K, Ohkuri T, Kumai T, Nagato T, Nozaki Y, Ishibashi K, Kosaka A, Nagata M, Harabuchi S, Ohara M, Oikawa K, Aoki N, Harabuchi Y, Celis E, Kobayashi H. Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma. Oncoimmunology 2018; 7:e1466771. [PMID: 30510853 DOI: 10.1080/2162402x.2018.1466771] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2018] [Revised: 04/13/2018] [Accepted: 04/13/2018] [Indexed: 12/19/2022] Open
Abstract
The human T cell receptor is capable of distinguishing between normal and post-translationally modified peptides. Because aberrant phosphorylation of cellular proteins is a hallmark of malignant transformation, the expression of the phosphorylated epitope could be an ideal antigen to combat cancer without damaging normal tissues. p53 activates transcription factors to suppress tumors by upregulating growth arrest and apoptosis-related genes. In response to DNA damage, p53 is phosphorylated at multiple sites including Ser33 and Ser37. Here, we identified phosphorylated peptide epitopes from p53 that could elicit effective T helper responses. These epitope peptides, p5322-41/Phospho-S33 and p5322-41/Phospho-S37, induced T helper responses against tumor cells expressing the phosphorylated p53 protein. Moreover, chemotherapeutic agents augmented the responses of such CD4 T cells via upregulation of phosphorylated p53. The upregulation of phosphorylated p53 expression by chemotherapy was confirmed in in vitro and xenograft models. We evaluated phosphorylated p53 expression in the clinical samples of oropharyngeal squamous cell carcinoma and revealed that 13/24 cases (54%) were positive for phosphorylated p53. Importantly, the lymphocytes specific for the phosphorylated p53 peptide epitopes were observed in the head and neck squamous cell cancer (HNSCC) patients. These results reveal that a combination of phosphorylated p53 peptides and chemotherapy could be a novel immunologic approach to treat HNSCC patients.
Collapse
Affiliation(s)
- Kenzo Ohara
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.,Department of Otolaryngology-Head and Neck surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Takayuki Ohkuri
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Takumi Kumai
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.,Department of Otolaryngology-Head and Neck surgery, Asahikawa Medical University, Asahikawa, Japan.,Department of Innovative Head & Neck Cancer Research and Treatment (IHNCRT), Asahikawa Medical University, Asahikawa, Japan
| | - Toshihiro Nagato
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.,Department of Otolaryngology-Head and Neck surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Yui Nozaki
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.,Department of Otolaryngology-Head and Neck surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Kei Ishibashi
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.,Department of surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Akemi Kosaka
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Marino Nagata
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Shohei Harabuchi
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.,Department of Otolaryngology-Head and Neck surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Mizuho Ohara
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.,Department of surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Kensuke Oikawa
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Naoko Aoki
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Yasuaki Harabuchi
- Department of Otolaryngology-Head and Neck surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Esteban Celis
- Cancer Immunology, Inflammation and Tolerance Program, Augusta University, Georgia Cancer Center, Augusta, GA
| | - Hiroya Kobayashi
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| |
Collapse
|
23
|
Komiyama K, Tanabe K, Fujimoto H, Oikawa K, Daida H, Nakamura M, Yamamoto T, Nagao K, Takayama M. P2747Validation of clinical scoring system for predicting in-hospital mortality in non ST-segment elevation myocardial infarction; Comparison with the GRACE risk score. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p2747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Uehara J, Ohkuri T, Kosaka A, Ishibashi K, Hirata Y, Ohara K, Nagato T, Oikawa K, Aoki N, Harabuchi Y, Ishida-Yamamoto A, Kobayashi H. Intratumoral injection of IFN-β induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb. Biochem Biophys Res Commun 2017. [DOI: 10.1016/j.bbrc.2017.06.072] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
25
|
Nagato T, Ohkuri T, Ohara K, Hirata Y, Kishibe K, Komabayashi Y, Ueda S, Takahara M, Kumai T, Ishibashi K, Kosaka A, Aoki N, Oikawa K, Uno Y, Akiyama N, Sado M, Takei H, Celis E, Harabuchi Y, Kobayashi H. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. Cancer Immunol Immunother 2017; 66:877-890. [PMID: 28349165 PMCID: PMC11028583 DOI: 10.1007/s00262-017-1987-x] [Citation(s) in RCA: 107] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2016] [Accepted: 03/08/2017] [Indexed: 12/14/2022]
Abstract
Nasal natural killer/T-cell lymphoma (NNKTL) is an aggressive neoplasm with poor therapeutic responses and prognosis. The programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) pathway plays an important role in immune evasion of tumor cells through T-cell exhaustion. The aim of the present study was to examine the expression of PD-L1 and PD-1 molecules in NNKTL. We detected the expression of PD-L1 in biopsy samples from all of the NNKTL patients studied. PD-L1 was found on both malignant cells and tumor-infiltrating macrophages, while PD-1-positive mononuclear cells infiltrated the tumor tissues in 36% of patients. Most significantly, soluble PD-L1 (sPD-L1) was present in sera of NNKTL patients at higher levels as compared to healthy individuals and the levels of serum sPD-L1 in patients positively correlated with the expression of PD-L1 in lymphoma cells of tumor tissues. In addition, the high-sPD-L1 group of patients showed significantly worse prognosis than the low-sPD-L1 group. Furthermore, we confirmed that membrane and soluble PD-L1 was expressed on the surface and in the culture supernatant, respectively, of NNKTL cell lines. The expression of PD-L1 was observed in tumor tissues and sera from a murine xenograft model inoculated with an NNKTL cell line. Our results suggest that sPD-L1 could be a prognostic predictor for NNKTL and open up the possibility of immunotherapy of this lymphoma using PD-1/PD-L1 axis inhibitors.
Collapse
Affiliation(s)
- Toshihiro Nagato
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan.
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan.
| | - Takayuki Ohkuri
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan
| | - Kenzo Ohara
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan
| | - Yui Hirata
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan
| | - Kan Kishibe
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan
| | - Yuki Komabayashi
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan
| | - Seigo Ueda
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan
| | - Miki Takahara
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan
| | - Takumi Kumai
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan
| | - Kei Ishibashi
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan
- Respiratory and Breast Center, Asahikawa Medical University Hospital, Asahikawa, Japan
| | - Akemi Kosaka
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan
| | - Naoko Aoki
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan
| | - Kensuke Oikawa
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan
| | - Yuji Uno
- Department of Surgical Pathology, Asahikawa Medical University Hospital, Asahikawa, Japan
| | - Naoko Akiyama
- Department of Surgical Pathology, Asahikawa Medical University Hospital, Asahikawa, Japan
| | - Masatoshi Sado
- Department of Surgical Pathology, Asahikawa Medical University Hospital, Asahikawa, Japan
| | - Hidehiro Takei
- Department of Surgical Pathology, Asahikawa Medical University Hospital, Asahikawa, Japan
| | - Esteban Celis
- Cancer Immunology, Inflammation and Tolerance Program, Georgia Cancer Center, Augusta University, Augusta, GA, USA
| | - Yasuaki Harabuchi
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan
| | - Hiroya Kobayashi
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan.
| |
Collapse
|
26
|
Ohkuri T, Kosaka A, Ishibashi K, Kumai T, Hirata Y, Ohara K, Nagato T, Oikawa K, Aoki N, Harabuchi Y, Celis E, Kobayashi H. Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site. Cancer Immunol Immunother 2017; 66:705-716. [PMID: 28243692 PMCID: PMC11028681 DOI: 10.1007/s00262-017-1975-1] [Citation(s) in RCA: 109] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2016] [Accepted: 02/12/2017] [Indexed: 12/25/2022]
Abstract
Stimulator of IFN genes (STING) spontaneously contributes to anti-tumor immunity by inducing type I interferons (IFNs) following sensing of tumor-derived genomic DNAs in the tumor-bearing host. Although direct injection of STING ligands such as cyclic diguanylate monophosphate (c-di-GMP) and cyclic [G(2',5')pA(3',5')p] (cGAMP) into the tumor microenvironment exerts anti-tumor effects through strong induction of type I IFNs and activation of innate and adaptive immunity, the precise events caused by STING in the tumor microenvironment remain to be elucidated. We describe here our finding that a CD45+ CD11bmid Ly6C+ cell subset transiently accumulated in mouse tumor microenvironment of 4T1 breast cancer, squamous cell carcinomas, CT26 colon cancer, or B16F10 melanoma tissue after intratumoral injection of cGAMP. The accumulated cells displayed a macrophage (M ) phenotype since the cells were positive for F4/80 and MHC class II and negative for Ly6G. Intratumoral cGAMP treatment did not induce Mφ accumulation in STING-deficient mice. Depletion of CD8+ T cell using anti-CD8 mAb impaired the anti-tumor effects of cGAMP treatment. Depletion of the Mφ using clodronate liposomes impaired the anti-tumor effects of cGAMP treatment. Functional analysis indicated that the STING-triggered tumor-migrating Mφ exhibited phagocytic activity, production of tumor necrosis factor alpha TNFα), and high expression levels of T cell-recruiting chemokines, Cxcl10 and Cxcl11, IFN-induced molecules, MX dynamin-like GTPase 1 (Mx1) and 2'-5' oligoadenylate synthetase-like 1 (Oasl1), nitric oxide synthase 2 (Nos2), and interferon beta 1 (Ifnb1). These results indicate that the STING-triggered tumor-migrating Mφ participate in the anti-tumor effects of STING-activating compounds.
Collapse
MESH Headings
- Animals
- Antineoplastic Agents/administration & dosage
- Antineoplastic Agents/pharmacology
- Breast Neoplasms/immunology
- Breast Neoplasms/pathology
- Breast Neoplasms/prevention & control
- Carcinoma, Squamous Cell/immunology
- Carcinoma, Squamous Cell/pathology
- Carcinoma, Squamous Cell/prevention & control
- Colonic Neoplasms/immunology
- Colonic Neoplasms/pathology
- Colonic Neoplasms/prevention & control
- Female
- Immunotherapy
- Injections, Intralesional
- Lymphocytes, Tumor-Infiltrating/drug effects
- Lymphocytes, Tumor-Infiltrating/immunology
- Macrophages/drug effects
- Macrophages/immunology
- Melanoma, Experimental/immunology
- Melanoma, Experimental/pathology
- Melanoma, Experimental/prevention & control
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Nucleotides, Cyclic/administration & dosage
- Nucleotides, Cyclic/pharmacology
- Phagocytosis
Collapse
Affiliation(s)
- Takayuki Ohkuri
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan.
| | - Akemi Kosaka
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
| | - Kei Ishibashi
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
- Respiratory and Breast Center, Asahikawa Medical University Hospital, Asahikawa, 078-8510, Japan
| | - Takumi Kumai
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, 078-8510, Japan
- Cancer Immunology, Inflammation and Tolerance Program, Augusta University GRU Cancer Center, Augusta, GA, 30912, USA
| | - Yui Hirata
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, 078-8510, Japan
| | - Kenzo Ohara
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, 078-8510, Japan
| | - Toshihiro Nagato
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, 078-8510, Japan
| | - Kensuke Oikawa
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
| | - Naoko Aoki
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan
| | - Yasuaki Harabuchi
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, 078-8510, Japan
| | - Esteban Celis
- Cancer Immunology, Inflammation and Tolerance Program, Augusta University GRU Cancer Center, Augusta, GA, 30912, USA
| | - Hiroya Kobayashi
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510, Japan.
| |
Collapse
|
27
|
Matsumoto Y, Segawa M, Kai T, Shinohara T, Nakatani T, Oikawa K, Hiroi K, Su Y, Hayashida H, Parker J, Zhang S, Kiyanagi Y. Recent Progress of Radiography and Tomography at the Energy-resolved Neutron Imaging System RADEN. ACTA ACUST UNITED AC 2017. [DOI: 10.1016/j.phpro.2017.06.022] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
28
|
Oikawa K, Odero GL, Nafez S, Ge N, Zhang D, Kobayashi H, Sate K, Kimura S, Tateno M, Albensi BC. Visinin-Like Protein-3 Modulates the Interaction Between Cytochrome b 5 and NADH-Cytochrome b 5 Reductase in a Ca 2+-Dependent Manner. Cell Biochem Biophys 2016; 74:449-457. [PMID: 27372904 DOI: 10.1007/s12013-016-0753-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2014] [Accepted: 06/23/2016] [Indexed: 12/01/2022]
Abstract
Visinin-like proteins (VILIPs) belong to the calcium sensor protein family. VILIP-1 has been examined as a cerebrospinal fluid biomarker and as a potential indicator for cognitive decline in Alzheimer's disease (AD). However, little is known about VILIP-3 protein biochemistry. We performed co-immunoprecipitation experiments to examine whether VILIP-3 can interact with reduced nicotine adenine dinucleotide (NADH)-cytochrome b 5 reductase. We also evaluated the specificity of cytochrome b 5 within the visinin-like protein subfamily and identified cytochrome P450 isoforms in the brain. In this study, we show that cytochrome b 5 has an affinity for hippocalcin, neurocalcin-δ, and VILIP-3, but not visinin-like protein-1. VILIP-3 was also shown to interact with NADH-cytochrome b 5 reductase in a Ca2+-dependent manner. These results suggest that VILIP-3, hippocalcin, and neurocalcin-δ provide a Ca2+-dependent modulation to the NADH-dependent microsomal electron transport. The results also suggest that future therapeutic strategies that target calcium-signaling pathways and VILIPs may be of value.
Collapse
Affiliation(s)
- Kensuke Oikawa
- Division of Neurodegenerative Disorders, St. Boniface Hospital Research, 351 Tache Ave./Room 4050, Winnipeg, MB, R2H 2A6, Canada
| | - Gary L Odero
- Division of Neurodegenerative Disorders, St. Boniface Hospital Research, 351 Tache Ave./Room 4050, Winnipeg, MB, R2H 2A6, Canada
| | - Solmaz Nafez
- Division of Neurodegenerative Disorders, St. Boniface Hospital Research, 351 Tache Ave./Room 4050, Winnipeg, MB, R2H 2A6, Canada.,Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, Canada
| | - Ning Ge
- Division of Neurodegenerative Disorders, St. Boniface Hospital Research, 351 Tache Ave./Room 4050, Winnipeg, MB, R2H 2A6, Canada
| | - Dali Zhang
- Division of Neurodegenerative Disorders, St. Boniface Hospital Research, 351 Tache Ave./Room 4050, Winnipeg, MB, R2H 2A6, Canada
| | - Hiroya Kobayashi
- Department of Pathology, and School of Nursing, Asahikawa Medical College, Asahikawa, 078-8510, Japan
| | - Keisuke Sate
- Department of Pathology, and School of Nursing, Asahikawa Medical College, Asahikawa, 078-8510, Japan
| | - Shoji Kimura
- Department of Pathology, and School of Nursing, Asahikawa Medical College, Asahikawa, 078-8510, Japan
| | - Masatoshi Tateno
- Department of Pathology, and School of Nursing, Asahikawa Medical College, Asahikawa, 078-8510, Japan
| | - Benedict C Albensi
- Division of Neurodegenerative Disorders, St. Boniface Hospital Research, 351 Tache Ave./Room 4050, Winnipeg, MB, R2H 2A6, Canada. .,Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, Canada.
| |
Collapse
|
29
|
Ishibashi K, Kumai T, Ohkuri T, Kosaka A, Nagato T, Hirata Y, Ohara K, Oikawa K, Aoki N, Akiyama N, Sado M, Kitada M, Harabuchi Y, Celis E, Kobayashi H. Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy. Oncoimmunology 2016; 5:e1169356. [PMID: 27471649 DOI: 10.1080/2162402x.2016.1169356] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2016] [Revised: 03/07/2016] [Accepted: 03/17/2016] [Indexed: 12/28/2022] Open
Abstract
Tumor immune escape has been a major problem for developing effective immunotherapy. The human leukocyte antigen G (HLA-G) is a non-classical MHC class I molecule whose primary function is to protect the fetus from the mother's immune system. While HLA-G is hardly found in normal adult tissues, various tumor cells are known to express it, aiding their escape from the immune system. Thus, HLA-G is an attractive immunotherapy target. CD4(+) helper T lymphocytes (HTLs) play an important role in the immune reaction against tumors by assisting in the generation and persistence of CD8(+) cytotoxic T lymphocytes (CTLs) or by displaying direct antitumor effects. We report here that HLA-G expression in breast cancer significantly correlates with a poor prognosis. Also, we describe that the MHC class II-binding peptide HLA-G26-40 was effective in eliciting tumor-reactive CD4(+) T cell responses. Furthermore, treatment with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine increased HLA-G expression in tumors and subsequently enhanced recognition by HLA-G26-40-specific HTLs. These findings predict that a combination immunotherapy targeting HLA-G together with a DNA methyltransferase inhibitor could be useful against some cancers.
Collapse
Affiliation(s)
- Kei Ishibashi
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan; Respiratory and Breast Center, Asahikawa Medical University Hospital, Asahikawa, Japan
| | - Takumi Kumai
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan; Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan; Cancer Immunology, Inflammation and Tolerance Program, Augusta University Cancer Center, Augusta, GA, USA
| | - Takayuki Ohkuri
- Department of Pathology, Asahikawa Medical University , Asahikawa, Japan
| | - Akemi Kosaka
- Department of Pathology, Asahikawa Medical University , Asahikawa, Japan
| | - Toshihiro Nagato
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University , Asahikawa, Japan
| | - Yui Hirata
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan; Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Kenzo Ohara
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan; Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Kensuke Oikawa
- Department of Pathology, Asahikawa Medical University , Asahikawa, Japan
| | - Naoko Aoki
- Department of Pathology, Asahikawa Medical University , Asahikawa, Japan
| | - Naoko Akiyama
- Department of Surgical Pathology, Asahikawa Medical University Hospital , Asahikawa, Japan
| | - Masatoshi Sado
- Department of Surgical Pathology, Asahikawa Medical University Hospital , Asahikawa, Japan
| | - Masahiro Kitada
- Respiratory and Breast Center, Asahikawa Medical University Hospital , Asahikawa, Japan
| | - Yasuaki Harabuchi
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University , Asahikawa, Japan
| | - Esteban Celis
- Cancer Immunology, Inflammation and Tolerance Program, Augusta University Cancer Center , Augusta, GA, USA
| | - Hiroya Kobayashi
- Department of Pathology, Asahikawa Medical University , Asahikawa, Japan
| |
Collapse
|
30
|
Kumai T, Oikawa K, Aoki N, Kimura S, Harabuchi Y, Kobayashi H. Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid. Head Neck 2015; 38:410-6. [PMID: 25352398 DOI: 10.1002/hed.23906] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/24/2014] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Epidermal growth factor receptor (EGFR)-targeted therapy has been widely accepted as a promising treatment for solid tumors. Steroid treatment is used to prevent adverse effect of anti-EGFR antibody; however, influence of steroids in the antitumor activity of targeted antibody remains poorly understood. Herein, we demonstrated the impact of steroids in induced antibody-dependent cellular cytotoxicity (ADCC) activity of natural killer (NK) cells by cetuximab. METHODS Various numbers of NK cells from healthy donors were co-cultured with tumor and/or cetuximab with or without dexamethasone. After incubation, NK cells, ADCC activity, survival, and activation markers expression were determined. RESULTS Clinical concentration of dexamethasone treatment clearly inhibited cetuximab-induced ADCC activity of NK cells against head and neck squamous cell carcinoma (HNSCC) and colon cancer. Dexamethasone decreased the activation marker CD69 expression on NK cells. CONCLUSION This is the first report that shows the negative affect of steroids in cancer treatment using therapeutic antibody. Attention needs to be paid for using steroids in tumor treatment.
Collapse
Affiliation(s)
- Takumi Kumai
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.,Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Kensuke Oikawa
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Naoko Aoki
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Shoji Kimura
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| | - Yasuaki Harabuchi
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | - Hiroya Kobayashi
- Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
| |
Collapse
|
31
|
Kumai T, Matsuda Y, Ohkuri T, Oikawa K, Ishibashi K, Aoki N, Kimura S, Harabuchi Y, Celis E, Kobayashi H. c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma. Oncoimmunology 2015; 4:e976077. [PMID: 25949874 DOI: 10.4161/2162402x.2014.976077] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2014] [Accepted: 10/09/2014] [Indexed: 12/14/2022] Open
Abstract
Background: The expression of c-Met and its ligand HGF plays a critical role in cell proliferation and is involved in numerous malignancies. Because c-Met expression and its role in NK/T-cell lymphoma remain unclear, we studied the expression and function of c-Met in NK/T-cell lymphoma cells. In addition, we investigated the possibility that c-Met could function as a tumor-associated antigen for helper T lymphocytes (HTLs). Methods: We evaluated whether HGF and c-Met were expressed in NK/T-cell lymphoma and the capacity of predicted c-Met HTL epitopes to induce antitumor responses in vitro. In addition, c-Met inhibitor was evaluated for the ability to inhibit TGF-β production in tumor and subsequently increase HTL recognition. Results: c-Met and HGF were expressed in NK/T-cell lymphoma cell lines, nasal NK/T-cell lymphoma specimens and patient serum samples. Moreover, HGF was shown to promote NK/T cell lymphoma (NKTCL) proliferation in an autocrine manner. Furthermore, we have identified three novel c-Met HTL epitopes that were restricted by several HLA-DR molecules. Notably, peptide-induced HTL lines directly recognized and killed c-Met expressing NK/T-cell lymphomas and various epithelial solid tumors. The c-Met specific HTLs could also recognize dendritic cells (DCs) pulsed with c-Met expressing tumor cell lysates. In addition, we observed that c-Met inhibition augmented HTL recognition by decreasing TGF-β production by tumor cells. Lastly, autophagy partly regulated the HTL responses against tumors. Conclusions: We identified novel c-Met HTL epitopes that can elicit effective antitumor responses against tumors expressing c-Met. Our results provide the rationale of combining c-Met targeting therapy and immunotherapy for NKTCLs and epithelial tumors.
Collapse
Key Words
- APCs, antigen presenting cells
- CD4+ helper T lymphocytes
- DC, dendritic cell
- EBV, Epstein-Barr virus
- HNSCC, head and neck squamous cell carcinoma
- HPLC, high-performance liquid chromatography
- HSP, heat shock protein
- HTLs, helper CD4+ T cells
- L-cell, mouse fibroblast cell line
- LDH, lactate dehydrogenase
- NK/T cell lymphoma
- NKTCL, natural killer/ T cell lymphoma
- PBMC, peripheral blood mononuclear cell
- PBS, phosphate buffered saline
- TCR, T cell receptor
- TGF-β
- TKI, tyrosine kinase receptor inhibitor
- autophagy
- c-Met
- head and neck squamous cell carcinoma
- immunotherapy
- major histocompatibility complex class II
- tumor antigens
Collapse
Affiliation(s)
- Takumi Kumai
- Department of Pathology; Asahikawa Medical University ; Asahikawa, Japan ; Department of Otolaryngology; Head and Neck Surgery; Asahikawa Medical University ; Asahikawa, Japan ; Cancer Immunology; Inflammation and Tolerance Program; Georgia Regents University Cancer Center ; Augusta, GA USA
| | - Yoshinari Matsuda
- Department of Pathology; Asahikawa Medical University ; Asahikawa, Japan
| | - Takayuki Ohkuri
- Department of Pathology; Asahikawa Medical University ; Asahikawa, Japan
| | - Kensuke Oikawa
- Department of Pathology; Asahikawa Medical University ; Asahikawa, Japan
| | - Kei Ishibashi
- Department of Pathology; Asahikawa Medical University ; Asahikawa, Japan
| | - Naoko Aoki
- Department of Pathology; Asahikawa Medical University ; Asahikawa, Japan
| | - Shoji Kimura
- Department of Pathology; Asahikawa Medical University ; Asahikawa, Japan
| | - Yasuaki Harabuchi
- Department of Otolaryngology; Head and Neck Surgery; Asahikawa Medical University ; Asahikawa, Japan
| | - Esteban Celis
- Cancer Immunology; Inflammation and Tolerance Program; Georgia Regents University Cancer Center ; Augusta, GA USA
| | - Hiroya Kobayashi
- Department of Pathology; Asahikawa Medical University ; Asahikawa, Japan
| |
Collapse
|
32
|
Nafez S, Oikawa K, Odero GL, Sproule M, Ge N, Schapansky J, Abrenica B, Hatherell A, Cadonic C, Zhang S, Song X, Kauppinen T, Glazner GW, Grilli M, Czubryt MP, Eisenstat DD, Albensi BC. Early growth response 2 (Egr-2) expression is triggered by NF-κB activation. Mol Cell Neurosci 2014; 64:95-103. [PMID: 25553923 DOI: 10.1016/j.mcn.2014.12.008] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2013] [Revised: 11/18/2014] [Accepted: 12/27/2014] [Indexed: 01/31/2023] Open
Abstract
Transcription factors are known to play multiple roles in cellular function. Investigators report that factors such as early growth response (Egr) protein and nuclear factor kappa B (NF-κB) are activated in the brain during cancer, brain injury, inflammation, and/or memory. To explore NF-κB activity further, we investigated the transcriptomes of hippocampal slices following electrical stimulation of NF-κB p50 subunit knockout mice (p50-/-) versus their controls (p50+/+). We found that the early growth response gene Egr-2 was upregulated by NF-κB activation, but only in p50+/+ hippocampal slices. We then stimulated HeLa cells and primary cortical neurons with tumor necrosis factor alpha (TNFα) to activate NF-κB and increase the expression of Egr-2. The Egr-2 promoter sequence was analyzed for NF-κB binding sites and chromatin immunoprecipitation (ChIP) assays were performed to confirm promoter occupancy in vivo. We discovered that NF-κB specifically binds to an NF-κB consensus binding site within the proximal promoter region of Egr-2. Luciferase assay demonstrated that p50 was able to transactivate the Egr-2 promoter in vitro. Small interfering RNA (siRNA)-mediated p50 knockdown corroborated other Egr-2 expression studies. We show for the first time a novel link between NF-κB activation and Egr-2 expression with Egr-2 expression directly controlled by the transcriptional activity of NF-κB.
Collapse
Affiliation(s)
- Solmaz Nafez
- St. Boniface Hospital Research; University of Manitoba, Dept. of Pharmacology & Therapeutics, Winnipeg MB, Canada
| | - Kensuke Oikawa
- St. Boniface Hospital Research; University of Manitoba, Dept. of Pharmacology & Therapeutics, Winnipeg MB, Canada
| | - Gary L Odero
- St. Boniface Hospital Research, Winnipeg MB, Canada
| | | | - Ning Ge
- St. Boniface Hospital Research, Winnipeg MB, Canada
| | - Jason Schapansky
- St. Boniface Hospital Research; University of Manitoba, Dept. of Pharmacology & Therapeutics, Winnipeg MB, Canada
| | | | | | - Chris Cadonic
- St. Boniface Hospital Research; University of Manitoba - Graduate Program in Biomedical Engineering, Winnipeg MB, Canada
| | - Shunzhen Zhang
- Manitoba Institute of Cell Biology, University of Manitoba, Winnipeg MB, Canada
| | - Xiaohua Song
- Dept. of Medical Genetics, University of Alberta, Edmonton AB, Canada
| | - Tiina Kauppinen
- University of Manitoba, Dept. of Pharmacology & Therapeutics, Winnipeg MB, Canada
| | - Gordon W Glazner
- St. Boniface Hospital Research; University of Manitoba, Dept. of Pharmacology & Therapeutics, Winnipeg MB, Canada
| | - Mariagrazia Grilli
- Dept. Pharmaceutical Sciences, University of Piemonte Orientale, Novara Italy
| | - Michael P Czubryt
- St. Boniface Hospital Research; University of Manitoba, Dept. of Physiology, Winnipeg MB, Canada
| | - David D Eisenstat
- Depts. of Pediatrics, Medical Genetics and Oncology, University of Alberta, Edmonton AB, Canada
| | - Benedict C Albensi
- St. Boniface Hospital Research; University of Manitoba - Graduate Program in Biomedical Engineering; University of Manitoba, Dept. of Pharmacology & Therapeutics, Winnipeg MB, Canada.
| |
Collapse
|
33
|
Furukori M, Imai K, Karasaki H, Watanabe K, Oikawa K, Miyokawa N, Taniguchi M, Furukawa H. Clinicopathological features of small nonfunctioning pancreatic neuroendocrine tumors. World J Gastroenterol 2014; 20:17949-17954. [PMID: 25548493 PMCID: PMC4273145 DOI: 10.3748/wjg.v20.i47.17949] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/25/2014] [Revised: 05/09/2014] [Accepted: 07/30/2014] [Indexed: 02/06/2023] Open
Abstract
AIM: To present our experiences in studying the clinicopathological features of small nonfunctioning pancreatic neuroendocrine tumors (NF-pNETs).
METHODS: The subjects included 9 patients with NF-pNETs who underwent pancreatectomy between April 1996 and September 2012. The surgical procedure, histopathological findings, and prognosis were assessed.
RESULTS: All tumors were incidentally detected by computed tomography. The median diameter was 10 mm (5-32 mm). One patient was diagnosed with von Hippel-Lindau disease, and the others were sporadic cases. For the histopathological findings, 7 patients were G1; 1 patient was G2; and 1 patient, whose tumor was 22 mm, had neuroendocrine carcinoma (NEC). One patient who had a tumor that was 32 mm had direct invasion to a regional lymph node and 1 patient with NEC, had regional lymph node metastases. Six of the 7 patients with sporadic NF-pNETs, excluding the patient with NEC, had tumors that were smaller than 10 mm. Tumors smaller than 10 mm showed no malignancy and lacked lymph node metastasis.
CONCLUSION: Sporadic NF-pNETs smaller than 10 mm tend to have less malignant potential. These findings suggest that lymphadenectomy may be omitted for small NF-pNETs after further investigation.
Collapse
|
34
|
Einama T, Uchida K, Taniguchi M, Ota Y, Watanabe K, Imai K, Karasaki H, Chiba A, Oikawa K, Miyokawa N, Furukawa H. Successful curative resection of gallbladder cancer following S-1 chemotherapy: A case report and review of the literature. Oncol Lett 2014; 8:2443-2447. [PMID: 25360167 PMCID: PMC4214413 DOI: 10.3892/ol.2014.2565] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2013] [Accepted: 08/01/2014] [Indexed: 11/05/2022] Open
Abstract
The symptoms of gallbladder cancer (GBC) are vague and non-specific. Therefore, GBC is often detected at an advanced or metastatic stage. The most effective treatment for GBC is surgical resection, however the majority of GBC cases are unresectable at the time of diagnosis. Therefore, numerous GBC patients undergo chemotherapy. This study reports the case of a 60-year-old female with GBC who underwent successful surgical curative resection following a single dose of the chemotherapeutic agent, S-1, twice daily for 4 weeks followed by a 14-day rest period for 36 months. S-1 is a novel orally administered drug composed of a combination of the 5-fluorouracil (5-FU) prodrug, tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and oteracil potassium in a 1:0.4:1 molar concentration ratio. The focus of the present study was the candidate factors that affect the therapeutic efficacy of S-1-based chemotherapy. In particular, the gene expression involved in the S-1 metabolic pathway was investigated by assessing the intratumoral dihydropyrimidine dehydrogenase (DPD), thymidylate synthase (TS) and orotate phosphoribosyltransferase gene expression. The surgical specimen exhibited high intratumoral DPD gene expression levels compared with those observed in previously reported non S-1 responsive cases of biliary tract cancer. Due to the results obtained in the current study, we hypothesize that CDHP enhanced the antitumor efficacy of 5-FU by inhibiting the excess DPD protein produced by the tumor.
Collapse
Affiliation(s)
- Takahiro Einama
- Division of Gastroenterological and General Surgery, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan ; Department of Surgery, Hokkaido Social Work Association Obihiro Hospital, Obihiro, Hokkaido 080-0805, Japan
| | - Koichiro Uchida
- Division of Gastroenterological and General Surgery, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan
| | - Masahiko Taniguchi
- Division of Gastroenterological and General Surgery, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan
| | - Yu Ota
- Division of Gastroenterological and General Surgery, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan
| | - Kenji Watanabe
- Division of Gastroenterological and General Surgery, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan
| | - Koji Imai
- Division of Gastroenterological and General Surgery, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan
| | - Hidenori Karasaki
- Division of Gastroenterological and General Surgery, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan
| | - Atsushi Chiba
- Digestive Disease Center, Asahikawa City Hospital, Hokkaido 070-8610, Japan
| | - Kensuke Oikawa
- Department of Surgical Pathology, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan
| | - Naoyuki Miyokawa
- Department of Surgical Pathology, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan
| | - Hiroyuki Furukawa
- Division of Gastroenterological and General Surgery, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan
| |
Collapse
|
35
|
Kumai T, Oikawa K, Aoki N, Kimura S, Harabuchi Y, Celis E, Kobayashi H. Tumor-derived TGF-β and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor. J Transl Med 2014; 12:265. [PMID: 25240937 PMCID: PMC4177691 DOI: 10.1186/s12967-014-0265-3] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2014] [Accepted: 09/15/2014] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND EGFR-targeted therapy is an attractive option for head and neck squamous cell carcinoma patients. We have recently reported the use of EGFR inhibitors as an adjunct treatment to enhance HLA-DR expression in tumor cells to improve cancer immunotherapy. Nevertheless, we observed that EGFR inhibitors resulted in decreased anti-tumor responses, regardless of upregulation of HLA-DR expression on the tumor cell. In this study, we specifically investigated the mechanisms by which EGFR inhibition modulated anti-tumor responses. METHODS An EGFR inhibitor erlotinib was used to assess the modulation of anti-tumor responses by tumor antigen-specific helper T cells. We then examined whether administration of the EGFR inhibitor altered tumor cytokine profiles and expression of immune-related molecules on tumor cells. RESULTS Despite the augmented HLA-DR expression on a gingival cancer cell line by EGFR inhibition, anti-tumor responses of EGFR reactive helper T cell clones against tumor cells were decreased. EGFR inhibition did not change the expression of CD80, CD86, or PD-L1 on the tumor cells. Conversely, production of transforming growth factor beta (TGF-β) and prostaglandin E2 was increased by EGFR inhibition, indicating that these immunosuppressive molecules were involved in diminishing tumor recognition by T cells. Significantly, attenuation of HTL responses against tumors after EGFR inhibition was reversed by the addition of anti-TGF-β antibody or COX2 inhibitors. CONCLUSIONS Targeting TGF-β and prostaglandin E2 may allow for improved outcomes for cancer patients treated with combination immunotherapy and EGFR inhibitors.
Collapse
|
36
|
Kumai T, Oikawa K, Aoki N, Kimura S, Harabuchi Y, Celis E, Kobayashi H. Tumor-derived TGF-β and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor. J Transl Med 2014. [PMID: 25240937 DOI: 10.1186/s12967-014-0265-3.] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND EGFR-targeted therapy is an attractive option for head and neck squamous cell carcinoma patients. We have recently reported the use of EGFR inhibitors as an adjunct treatment to enhance HLA-DR expression in tumor cells to improve cancer immunotherapy. Nevertheless, we observed that EGFR inhibitors resulted in decreased anti-tumor responses, regardless of upregulation of HLA-DR expression on the tumor cell. In this study, we specifically investigated the mechanisms by which EGFR inhibition modulated anti-tumor responses. METHODS An EGFR inhibitor erlotinib was used to assess the modulation of anti-tumor responses by tumor antigen-specific helper T cells. We then examined whether administration of the EGFR inhibitor altered tumor cytokine profiles and expression of immune-related molecules on tumor cells. RESULTS Despite the augmented HLA-DR expression on a gingival cancer cell line by EGFR inhibition, anti-tumor responses of EGFR reactive helper T cell clones against tumor cells were decreased. EGFR inhibition did not change the expression of CD80, CD86, or PD-L1 on the tumor cells. Conversely, production of transforming growth factor beta (TGF-β) and prostaglandin E2 was increased by EGFR inhibition, indicating that these immunosuppressive molecules were involved in diminishing tumor recognition by T cells. Significantly, attenuation of HTL responses against tumors after EGFR inhibition was reversed by the addition of anti-TGF-β antibody or COX2 inhibitors. CONCLUSIONS Targeting TGF-β and prostaglandin E2 may allow for improved outcomes for cancer patients treated with combination immunotherapy and EGFR inhibitors.
Collapse
|
37
|
Shonaka T, Inagaki M, Akabane H, Yanagida N, Shomura H, Yanagawa N, Oikawa K, Nakano S. Total pancreatectomy for metachronous mixed acinar-ductal carcinoma in a remnant pancreas. World J Gastroenterol 2014; 20:11904-11909. [PMID: 25206298 PMCID: PMC4155384 DOI: 10.3748/wjg.v20.i33.11904] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2014] [Revised: 03/28/2014] [Accepted: 04/23/2014] [Indexed: 02/06/2023] Open
Abstract
In October 2009, a 71-year-old female was diagnosed with a cystic tumor in the tail of the pancreas with an irregular dilatation of the main pancreatic duct in the body and tail of the pancreas. A distal pancreatectomy with splenectomy, and partial resection of the duodenum, jejunum and transverse colon was performed. In March 2011, a follow-up computed tomography scan showed a low density mass at the head of the remnant pancreas. We diagnosed it as a recurrence of the tumor and performed a total pancreatectomy for the remnant pancreas. In the histological evaluation of the resected specimen of the distal pancreas, the neoplastic cells formed an acinar and papillary structure that extended into the main pancreatic duct. Mucin5AC, α1-antitrypsin (α-AT) and carcinoembryonic antigen (CEA) were detected in the tumor cells by immunohistochemistry. In the resected head of the pancreas, the tumor was composed of both acinar and ductal elements with a mottled pattern. The proportions of each element were approximately 40% and 60%, respectively. Strongly positive α-AT cells were detected in the acinar element. Some tumor cells were also CEA positive. However, the staining for synaptophysin and chromogranin A was negative in the tumor cells. Ultimately, we diagnosed the tumor as a recurrence of mixed acinar-ductal carcinoma in the remnant pancreas. In conclusion, we report here a rare case of repeated pancreatic resection for multicentric lesions of mixed acinar-ductal carcinoma of the pancreas.
Collapse
MESH Headings
- Aged
- Biomarkers, Tumor/analysis
- Biopsy
- Carcinoma, Pancreatic Ductal/chemistry
- Carcinoma, Pancreatic Ductal/pathology
- Carcinoma, Pancreatic Ductal/surgery
- Cholangiopancreatography, Endoscopic Retrograde
- Endosonography
- Female
- Humans
- Immunohistochemistry
- Multimodal Imaging
- Neoplasm Recurrence, Local
- Neoplasms, Complex and Mixed/chemistry
- Neoplasms, Complex and Mixed/pathology
- Neoplasms, Complex and Mixed/surgery
- Neoplasms, Second Primary/pathology
- Neoplasms, Second Primary/surgery
- Pancreatectomy/adverse effects
- Pancreatic Neoplasms/chemistry
- Pancreatic Neoplasms/pathology
- Pancreatic Neoplasms/surgery
- Positron-Emission Tomography
- Predictive Value of Tests
- Reoperation
- Tomography, X-Ray Computed
- Treatment Outcome
Collapse
|
38
|
Kanno K, Minami-Hori M, Ishida-Yamamoto A, Komura K, Oikawa K, Miyokawa N, Iizuka H. Cutaneous lesions of Kikuchi's disease: Evolution of histopathological findings. J Dermatol 2014; 41:736-8. [DOI: 10.1111/1346-8138.12557] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2014] [Accepted: 06/05/2014] [Indexed: 11/30/2022]
Affiliation(s)
- Kyoko Kanno
- Department of Dermatology; Asahikawa Medical University; Asahikawa Japan
| | - Masako Minami-Hori
- Department of Dermatology; Asahikawa Medical University; Asahikawa Japan
| | | | - Keiji Komura
- Department of Internal Medicine; Asahikawa Medical University; Asahikawa Japan
| | - Kensuke Oikawa
- Department of Pathology; Asahikawa Medical University; Asahikawa Japan
| | - Naoyuki Miyokawa
- Department of Pathology; Asahikawa Medical University; Asahikawa Japan
| | - Hajime Iizuka
- Department of Dermatology; Asahikawa Medical University; Asahikawa Japan
| |
Collapse
|
39
|
Kumai T, Ishibashi K, Oikawa K, Matsuda Y, Aoki N, Kimura S, Hayashi S, Kitada M, Harabuchi Y, Celis E, Kobayashi H. Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53. Cancer Immunol Immunother 2014; 63:469-78. [PMID: 24633296 PMCID: PMC11028558 DOI: 10.1007/s00262-014-1533-z] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2014] [Accepted: 03/03/2014] [Indexed: 12/22/2022]
Abstract
Posttranslational modifications regulate the function and stability of proteins, and the immune system is able to recognize some of these modifications. Therefore, the presence of posttranslational modifications increases the diversity of potential immune responses to a determinant antigen. The stimulation of tumor-specific CD4(+) helper T lymphocytes (HTLs) is considered important for the production of anti-tumor antibodies by B cells and for the generation and persistence of CD8(+) cytotoxic T lymphocytes, and in some instances, HTLs can directly reduce tumor cell growth. Identification of MHC class II-restricted peptide epitopes from tumor-associated antigens including those generated from posttranslational protein modifications should enable the improvement of peptide-based cancer immunotherapy. We describe here an MHC class II binding peptide from the tumor protein p53, which possesses an acetylated lysine at position 120 (p53110-124/AcK120) that is effective in eliciting CD4(+) T cell responses specific for the acetylated peptide. Most importantly, the acetylated peptide-reactive CD4 HTLs recognized the corresponding naturally processed posttranslational modified epitope presented by either dendritic cells loaded with tumor cell lysates or directly on tumors expressing p53 and the restricting MHC class II molecules. Treatment of tumor cells with a histone deacetylase inhibitor augmented their recognition by the p53110-124/AcK120-reactive CD4(+) T cells. These findings prove that the epitope p53110-124/AcK120 is immunogenic for anti-tumor responses and is likely to be useful for cancer immunotherapy.
Collapse
Affiliation(s)
- Takumi Kumai
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510 Japan
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, 078-8510 Japan
| | - Kei Ishibashi
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510 Japan
- Respiratory and Breast Center, Asahikawa Medical University Hospital, Asahikawa, 078-8510 Japan
| | - Kensuke Oikawa
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510 Japan
| | - Yoshinari Matsuda
- Respiratory and Breast Center, Asahikawa Medical University Hospital, Asahikawa, 078-8510 Japan
| | - Naoko Aoki
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510 Japan
| | - Shoji Kimura
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510 Japan
| | - Satoshi Hayashi
- Respiratory and Breast Center, Asahikawa Medical University Hospital, Asahikawa, 078-8510 Japan
| | - Masahiro Kitada
- Respiratory and Breast Center, Asahikawa Medical University Hospital, Asahikawa, 078-8510 Japan
| | - Yasuaki Harabuchi
- Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, 078-8510 Japan
| | - Esteban Celis
- Cancer Immunology, Inflammation and Tolerance Program, Department of Medicine, Georgia Regents University Cancer Center, 1410 Laney Walker Boulevard, CN-4121, Augusta, GA 30912 USA
| | - Hiroya Kobayashi
- Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1, Asahikawa, 078-8510 Japan
| |
Collapse
|
40
|
Konno Y, Fujiya M, Tanaka K, Sakatani A, Shimoda M, Hayashi A, Muto M, Inoue M, Sakamoto J, Oikawa K, Ueno N, Inaba Y, Moriichi K, Kohgo Y. A therapeutic barium enema is a practical option to control bleeding from the appendix. BMC Gastroenterol 2013; 13:152. [PMID: 24156777 PMCID: PMC4020223 DOI: 10.1186/1471-230x-13-152] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2012] [Accepted: 10/17/2013] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Acute lower gastrointestinal hemorrhage originating from the appendix is rare and often intractable, because it is almost impossible to approach the bleeding point by endoscopy. We herein describe the first case of bleeding from the appendix, which was successively controlled by a therapeutic barium enema administered into the appendix. CASE PRESENTATION A 71-year-old male visited our hospital because of melena. He has been receiving an anti-coagulation drug, ticlopidine hydrochloride, for 10 years. By an emergency colonoscopy, a hemorrhage was detected in the appendix, and the lesion responsible for the bleeding was regarded to exist in the appendix. Two hundred milliliters of 50 W/V% barium was sprayed into the orifice of the appendix using a spraying tube. The bleeding could thus be immediately stopped, and a radiological examination revealed the accumulation of barium at the cecum and the orifice of the appendix. The barium accumulation disappeared by the next day, and no obvious anal bleeding was observed. Two weeks after stopping the bleeding from the appendix, an appendectomy was performed to prevent any further refractory hemorrhaging. The patient has had no complaints of any abdominal symptoms or anal bleeding for 10 months. CONCLUSIONS A therapeutic barium enema is a useful procedure to control bleeding from the appendix and to avoid emergency surgery, such as partial cecectomy and hemicolectomy.
Collapse
Affiliation(s)
| | - Mikihiro Fujiya
- Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido 078-8510, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Kumai T, Matsuda Y, Oikawa K, Aoki N, Kimura S, Harabuchi Y, Celis E, Kobayashi H. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy. Br J Cancer 2013; 109:2155-66. [PMID: 24045666 PMCID: PMC3798972 DOI: 10.1038/bjc.2013.577] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2013] [Revised: 08/23/2013] [Accepted: 08/28/2013] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Head and neck squamous cell carcinoma (HNSCC) is a major cause of cancer-related morbidity and mortality worldwide. Epidermal growth factor receptor (EGFR)-targeted therapy is an attractive strategy alternative to conventional cancer treatments for HNSCC, but its efficacy remains controversial. T-cell-based immunotherapy has been proposed as a novel therapeutic approach to improve the clinical outcome for HNSCC. In this study, we report human epidermal receptor (HER) family epitopes that induced CD4 T-cell responses to HNSCC. The results provide support for a novel strategy to treat HNSCC by combining EGFR-targeted therapy with T-cell-based immunotherapy. METHODS We evaluated the capacity of predicted CD4 T-cell peptide epitopes from EGFR to induce antitumour immune responses in vitro. In addition, EGFR inhibitors were evaluated for their ability to augment tumour MHC class II expression in HNSCC cell lines and subsequently increase T-cell recognition. RESULTS Among several predicted peptide epitopes, EGFR875-889 elicited CD4 T-cell responses that were restricted by HLA-DR4, DR15, or DR53 molecules, indicating that the peptide functions as a promiscuous T-cell epitope. The peptide-reactive T cells responded to autologous dendritic cells loaded with EGFR-expressing tumour cell lysates, indicating that these epitopes are naturally processed. In addition, the CD4 T cells were capable of directly recognising and killing HNSCC cells expressing EGFR and the appropriate HLA class II molecule. T cells reactive with the EGFR875-889 epitope could be detected in the blood of HNSCC patients. EGFR875-889-reactive CD4 T cells were also able to recognise several peptide analogues derived from homologous regions of EGFR family members, HER-2, HER-3 and c-MET. Finally, we examined the effects of EGFR tyrosine kinase inhibition or EGFR-blocking antibodies on CD4 T-cell tumour reactivity. Treatment of tumour cells with the EGFR inhibitors enhanced tumour recognition by EGFR875-889-reactive T cells presumably due to the upregulation of HLA-DR expression in the HNSCC cells. CONCLUSION We identified novel CD4 T-cell EGFR epitopes and amongst these, EGFR875-889 functions as a promiscuous helper T-cell epitope that can elicit effective antitumour T-cell responses against tumours expressing HER family members and c-MET. These observations should facilitate the translation of T-cell-based immunotherapy into the clinic for the treatment of HNSCC and provide a rational basis for EGFR inhibition, immune-targeted combination therapy.
Collapse
Affiliation(s)
- T Kumai
- 1] Department of Pathology, Asahikawa Medical University, Asahikawa, Japan [2] Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Kitada M, Matuda Y, Hayashi S, Ishibashi K, Oikawa K, Miyokawa N, Ohsaki Y. IgG4-related lung disease showing high standardized uptake values on FDG-PET: report of two cases. J Cardiothorac Surg 2013; 8:160. [PMID: 23800259 PMCID: PMC3717047 DOI: 10.1186/1749-8090-8-160] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2013] [Accepted: 06/21/2013] [Indexed: 01/06/2023] Open
Abstract
Immunoglobulin G4 (IgG4)-related lung disease is a disease in which IgG4-positive plasma cells and lymphocytes infiltrate lung tissues along with immunohistochemically evident fibrous interstitial proliferation in the background, in addition to hyper-IgG4 disease. The diagnosis of this disease can be difficult. Here, we report 2 cases with IgG4-related lung disease that was difficult to differentiate from malignant tumors because both cases had pulmonary lesions showing high standardized uptake values (SUV) on positron emission tomography (PET). Case 1: A 75-year-old man under treatment for autoimmune pancreatitis and diabetes mellitus was noted to have multiple nodular opacities in both lungs and a mass density in the right paravertebral region on computed tomography (CT). As high SUVmax was noted for both lesions on exploration by fluorodeoxyglucose (FDG)-PET/CT, an advanced malignant tumor was diagnosed and a video-assisted thoracoscopic (VATS) biopsy was performed and diagnosed IgG4-related lung disease. Case 2: A 48-year-old woman consulted our clinic with a chief complaint of bloody sputum. Chest CT revealed a mass density with 12-, 13-, and 16-mm spiculations in the S2 segment of the right upper lobe and irregular thickening of the pleura including the paravertebral region. The lesion was a mass showing high SUV in the S2 segment on FDG-PET. Malignancy was suspected from the imaging findings, and a VATS biopsy was performed and diagnosed IgG4-related lung disease. Actively undertaking VATS biopsy in cases with this disease is valuable for making the differential diagnosis between malignant tumors and IgG4-related lung disease, since the diagnosis can be difficult in some patients showing high SUV.
Collapse
Affiliation(s)
- Masahiro Kitada
- Department of Respiratory Center, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, Hokkaido 078-8510, Japan.
| | | | | | | | | | | | | |
Collapse
|
43
|
Kiyanagi Y, Shinohara T, Kai T, Kamiyama T, Sato H, Kino K, Aizawa K, Arai M, Harada M, Sakai K, Oikawa K, Ooi M, Maekawa F, Iikura H, Sakai T, Matsubayashi M, Segawa M, Kureta M. Present Status of Research on Pulsed Neutron Imaging in Japan. ACTA ACUST UNITED AC 2013. [DOI: 10.1016/j.phpro.2013.03.012] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
44
|
Oikawa K, Odero GL, Platt E, Neuendorff M, Hatherell A, Bernstein MJ, Albensi BC. NF-κB p50 subunit knockout impairs late LTP and alters long term memory in the mouse hippocampus. BMC Neurosci 2012; 13:45. [PMID: 22553912 PMCID: PMC3394209 DOI: 10.1186/1471-2202-13-45] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2012] [Accepted: 05/03/2012] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Nuclear factor kappa B (NF-κB) is a transcription factor typically expressed with two specific subunits (p50, p65). Investigators have reported that NF-κB is activated during the induction of in vitro long term potentiation (LTP), a paradigm of synaptic plasticity and correlate of memory, suggesting that NF-κB may be necessary for some aspects of memory encoding. Furthermore, NF-κB has been implicated as a potential requirement in behavioral tests of memory. Unfortunately, very little work has been done to explore the effects of deleting specific NF-κB subunits on memory. Studies have shown that NF-κB p50 subunit deletion (p50-/-) leads to memory deficits, however some recent studies suggest the contrary where p50-/- mice show enhanced memory in the Morris water maze (MWM). To more critically explore the role of the NF-κB p50 subunit in synaptic plasticity and memory, we assessed long term spatial memory in vivo using the MWM, and synaptic plasticity in vitro utilizing high frequency stimuli capable of eliciting LTP in slices from the hippocampus of NF-κB p50-/- versus their controls (p50+/+). RESULTS We found that the lack of the NF-κB p50 subunit led to significant decreases in late LTP and in selective but significant alterations in MWM tests (i.e., some improvements during acquisition, but deficits during retention). CONCLUSIONS These results support the hypothesis that the NF-κ p50 subunit is required in long term spatial memory in the hippocampus.
Collapse
Affiliation(s)
- Kensuke Oikawa
- Div'n, of Neurodegenerative Disorders, St, Boniface Hospital Research, Winnipeg, MB, Canada
| | | | | | | | | | | | | |
Collapse
|
45
|
Muto M, Sato R, Fujiya M, Tanaka K, Serikawa S, Hayashi A, Konno Y, Sakamoto J, Nishikawa T, Oikawa K, Ueno N, Ikuta K, Mizukami Y, Tanno S, Watari J, Kohgo Y. Pseudo-diverticular formation due to a cytomegalovirus infection in the colorectum. Dig Endosc 2012; 24:193. [PMID: 22507100 DOI: 10.1111/j.1443-1661.2011.01188.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
46
|
Hayashi S, Kitada M, Sato K, Matsuda Y, Ishibashi K, Oikawa K, Miyokawa N, Hirata S. Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers. Breast Cancer 2012; 21:47-51. [PMID: 22467403 DOI: 10.1007/s12282-012-0353-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2012] [Accepted: 03/07/2012] [Indexed: 10/28/2022]
Abstract
BACKGROUND The 2011 St. Gallen Consensus Statement advocated using histological grade (HG) as a proliferation marker of breast cancer (BC) if reliable Ki67 labeling index (Ki67-LI) assessment is not available. However, it has been difficult to evaluate tumor aggressiveness in case of HG2. METHODS A total of 259 cases of BC were assessed for HG, Ki67-LI and other clinicopathological features. The cut point for Ki67-LI was interpreted as low and high using a 14% threshold. RESULTS The average age at diagnosis was 58.2 years (range 28-86); 64.9% of the patients were postmenopausal. Of the 259 cases, 151 were stage I, 78 were stage II, 29 were stage III, and 1 was stage IV. The subtypes based on immunohistochemical staining were 60 cases of luminal A (LA) type (23.2%), 37 cases of luminal B (LB) (HER2-) type (14.3%), 91 cases of LB (HER2+) type (35.1%), 40 cases of human epidermal growth factor receptor 2 (HER2) type (15.4%) and 31 cases of triple negative (TN) type (12%). HG was 1 (89 cases, 34.4 %), 2 (117 cases, 45.2%) and 3 (53 cases, 20.5%). High Ki67-LI cases were observed in HG1 (37.1%), HG2 (56.4%) and HG3 (96.2%). Especially in cases of HG2, high Ki67-LI cases were observed in 0 % of LA type, 100% of LB (HER2-) type, 71.2% of LB (HER2+) type, 68.8% of HER2 type and 40.0% of TN type. The average Ki67-LI was 6.0 ± 3.8 (LA type), 31.4 ± 15.7 [LB (HER2-) type], 20.2 ± 14.8 [LB (HER2+) type], 32.7 ± 21.9 (HER2 type) and 55.7 ± 32.2 (TN type). All LA-type cases and 66.7% of LB (HER2+)-type cases were low Ki67-LI. CONCLUSIONS Our study demonstrates that all LA-type cases and most HG1 of LB (HER2+)-type cases are low proliferative. However, HG was not informative enough for estimating tumor proliferation in cases of LB (HER2-), HER2 and TN types. It is necessary to add other proliferation tools such as the gene expression profiling tool and Ki67-LI except in LA and HG1 of LB (HER2+)-type cases.
Collapse
Affiliation(s)
- Satoshi Hayashi
- Breast Center, Asahikawa Medical University Hospital, Midorigaoka-Higashi 2-1-1-1, Asahikawa, Hokkaido, 078-8510, Japan,
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Brown PJ, Gandy AP, Kainuma R, Kanomata T, Neumann KU, Oikawa K, Ouladdiaf B, Sheikh A, Ziebeck KRA. The field and temperature dependence of the magnetic and structural properties of the shape memory compound Ni(1.84)Mn(1.64)In(0.52). J Phys Condens Matter 2011; 23:456004. [PMID: 22037587 DOI: 10.1088/0953-8984/23/45/456004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Magnetization and high resolution neutron powder diffraction measurements have been made on the magnetic shape memory alloy Ni(1.84)Mn(1.64)In(0.52). The compound undergoes a broad structural phase transition, which on heating starts at ∼150 K and finishes at ∼215 K. On cooling there is a ∼20 K hysteresis. The high temperature parent phase is cubic (a = 5.988 Å) with the L2(1) structure in which the excess Mn atoms occupy the vacancies on the Ni and In sites. The magnetic moment is located mainly on the Mn atoms with the same magnitude on both the 4a (Mn) and 4b (In) sites. The low temperature martensite is monoclinic with parameters a = 4.405(2), b = 5.553(2), c = 12.950(2) Å, β = 86.47(10)° and space group P2/m. The magnetic properties of the martensitic phase are complex and indicate metamagnetic behaviour.
Collapse
Affiliation(s)
- P J Brown
- Department of Physics, Loughborough University, LE11 3TU, UK. Institut Laue Langevin, BP 156, 38042 Grenoble, France
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Kiyanagi R, Oikawa K, Tamura I, Ohhara T, Kawasaki T, Kaneko K, Kimura H, Takahashi M, Kiyotani T, Nakao A, Hanashima T, Munakata K, Arai M, Noda Y, Ohshima K. Construction of new time-of-flight single-crystal diffractometer SENJU at J-PARC. Acta Crystallogr A 2011. [DOI: 10.1107/s0108767311093524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
49
|
Ohhara T, Oikawa K, Tamura I, Kaneko K, Kiyanagi R, Kawasaki T, Nakao A, Hanashima T, Munakata K, Nakatani T, Inamura Y, Ito T, Takeda M, Yamazaki D, Hayashida H. Development of software for a new time-of-flight single crystal diffractometer SENJU at J-PARC. Acta Crystallogr A 2011. [DOI: 10.1107/s0108767311083498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
50
|
Oikawa K, Ohkohchi N, Sato M, Satomi S. The effects of the elimination of Kupffer cells in the isolated perfused liver from non-heart-beating rat. Transpl Int 2011. [DOI: 10.1111/j.1432-2277.2000.tb02109.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|